Eli Lilly and Co (NYSE:LLY) said on Tuesday it will acquire Centessa Pharmaceuticals PLC (NASDAQ:CNTA) for $38 per share in cash, with a potential contingent value right worth up to $9 per share, valuing the deal at approximately $6.3 billion upfront and up to $7.8 billion including milestones.
The acquisition adds Centessa’s sleep-wake disorder pipeline, including its lead asset cleminorexton, to Lilly’s neuroscience business.
Cleminorexton is being evaluated in clinical trials for narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia.
Centessa shares surged about 45% in early trading on Tuesday, while Lilly shares rose roughly 2.9%.
BMO Capital reiterated an Outperform rating and a $1,300 price target on Eli Lilly shares following the acquisition announcement. The firm said the deal is positive for Lilly, noting the company is acquiring from a position of strength and diversifying its business ahead of any major loss of exclusivity events.
The deal highlights Lilly’s effort to broaden its portfolio beyond metabolic treatments and strengthen its presence in neuroscience.
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.
The proposed transactions may contain terms that could limit superior competing offers.
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
, /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)'s sale to Biogen Inc. for $41.00 per share in cash and a nontransferable contingent value right for the right to receive two payments of $2.00 per share each, contingent on certain annual global net sales thresholds being met for SYFOVRE. If you are an Apellis shareholder, click here to learn more about your legal rights and options.
Centessa Pharmaceuticals plc (NASDAQ: CNTA)'s sale to Eli Lilly and Company for $38.00 in cash per share plus one non-transferrable contingent value right entitling the holder to receive up to an aggregate of $9.00 subject to the achievement of certain milestones. If you are a Centessa shareholder, click here to learn more about your legal rights and options.
Allbirds, Inc.'s (NASDAQ: BIRD)'s sale of its intellectual property and certain other assets to American Exchange Group for $39 million. If you are an Allbirds shareholder, click here to learn more about your legal rights and options.
On behalf of shareholders, Halper Sadeh LLC may seek increased consideration, additional disclosures and information, or other relief and benefits.
Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Halper Sadeh LLC
Daniel Sadeh, Esq.
Zachary Halper, Esq.
One World Trade Center
85th Floor
New York, NY 10007
(212) 763-0060
[email protected]
[email protected]
https://www.halpersadeh.com
Stocks are eyeing a strong March finish, with the Dow Jones Industrial Average (DJI) up 514 points. The Nasdaq Composite (IXIC) and S&P 500 Index (SPX) sport outsized leads of their own, with all three major indexes eyeing their best single-session gains since Feb. 6. Investors are brushing off elevated oil prices after President Donald Trump appeared willing to end the war with Iran, even if the Strait of Hormuz remained mostly shuttered.
Despite today's gains, all three benchmarks remain on track for severe monthly and quarterly losses. In fact, the Dow and S&P 500 are pacing for their worst months since September 2022 and their worst quarters since June 2022.
Nike stock making headway before earnings. Marvell's $2 billion AI partnership with Nvidia. Plus, pharma buyout buzz; earnings boost FDS; and Constellation's dismal forecast.
Centessa Pharmaceuticals PLC (NASDAQ:CNTA) stock is surging today, last seen 44.7% higher to trade at $39.90 on news that Eli Lilly (LLY) will acquire the company for $6.3 billion. Options traders are targeting CNTA in response, with 2,981 calls and 1,077 puts exchanged so far -- 19 times the volume typically seen at this point. Most active is the April 30 call, with positions being sold to open at the May 40 put. CNTA is eyeing its best day on record and earlier surged to a fresh all-time high of $40.26. In the last nine months, the stock has added 203.8%.
Factset Research Systems Inc (NYSE:FDS) stock is leading the SPX today, up 6.3% to trade at $217.43 at last check. This surge comes after the financial data and software giant reported better-than-expected fiscal-second quarter earnings and revenue. FDS is eyeing its fourth-straight win and best single-day percentage pop since June 2022. The shares are also eyeing a close above their 40-day moving average for the first time since January, but still carry a 24.2% deficit for 2026.
Meanwhile, Constellation Energy Corp (NASDAQ:CEG) stock is at the bottom of the SPX, last seen down 8.7% at $272.59, after the company issued a 2026 profit forecast that came in below expectations. CEG has been struggling to conquer resistance from the 80-day moving average since late February. Year to date, the energy stock has shed 22.7%.
Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact , /PRNewswire/ -- LLP is investigating Centessa (NASDAQ: CNTA) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Lilly.
Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you.
In the transaction, Centessa stockholders will receive $38.00 per share in cash plus contingent value rights worth up to $9.00 per share. The contingent value rights entitle holders to receive up to three milestone payments: $2.00 upon U.S. FDA approval for narcolepsy type 2 treatment, $5.00 for idiopathic hypersomnia approval, and $2.00 for any indication approval before January 1, 2030. All approvals must occur within five years of transaction closing.
Centessa insiders will receive substantial benefits as part of change of control arrangements.
The transaction agreement unreasonably limits competing transactions for Centessa by imposing a significant penalty if Centessa accepts a competing bid. We are investigating the conduct of the Centessa board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.
We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
Eli Lilly has agreed to acquire Centessa Pharmaceuticals in a deal valued at up to $7.8 billion, marking a significant expansion of the drugmaker’s neuroscience portfolio into sleep medicine.
Under the terms announced Tuesday, Lilly will pay $38 per share in cash upfront, valuing Centessa at approximately $6.3 billion.
The offer represents a 38% premium to Centessa’s Monday closing price of $27.58.
Shareholders will also receive nontransferable contingent value rights worth up to an additional $9 per share, tied to future regulatory approvals of Centessa’s drug candidates.
The total potential consideration brings the deal value to $47 per share or about $7.8 billion.
The transaction is expected to close in the third quarter, subject to regulatory approval.
Lilly’s shares rose 2.75% following the announcement, while Centessa’s US-listed ADR surged 45%, reflecting investor optimism about the strategic fit and future potential of the pipeline.
The acquisition centers on Centessa’s experimental drug portfolio targeting excessive daytime sleepiness, including narcolepsy and idiopathic hypersomnia.
These conditions impair the ability to stay awake during the day and are part of a broader category of neurological disorders.
Centessa’s lead candidate, cleminorexton, has demonstrated what Lilly described as a potential best-in-class profile in Phase 2a studies.
Another candidate, ORX142, is also part of the agreement, with milestone payments tied to approvals from the US Food and Drug Administration.
The therapies belong to a new class of drugs known as orexin agonists, which target the brain’s sleep-wake regulation system. The approach is drawing increasing interest across the pharmaceutical industry.
“Orexin receptor biology represents one of the most compelling mechanistic opportunities in neuroscience as a direct intervention on the master switch of the sleep-wake cycle,” Dr. Carole Ho, president of Lilly Neuroscience, said in a statement. “Centessa has assembled a portfolio with the breadth and depth to improve wakefulness across a broad array of indications.”
Beyond narcolepsy, these drugs may have applications in conditions such as Alzheimer’s disease and depression, where drowsiness is a common symptom.
Centessa is not expected to be first to market in the orexin agonist category.
A competing treatment from Takeda is currently under FDA review and could receive approval later this year.
Analysts estimate the market for orexin-based treatments could reach between $15 billion and $20 billion if roughly a quarter of eligible patients seek treatment.
Wider adoption across additional neurological conditions could further expand that opportunity.
Despite promising mid-stage data, Centessa’s lead drug is not expected to gain approval until 2028, according to analyst estimates. However, early results suggest it could emerge as a best-in-class option.
The deal underscores Lilly’s broader strategy of reinvesting proceeds from its successful obesity and diabetes drugs, including Zepbound and Mounjaro, into new therapeutic areas.
It also follows a series of recent acquisitions. Earlier this year, Lilly announced plans to acquire Orna Therapeutics for up to $2.4 billion and Ventyx Biosciences for about $1.2 billion.
With the Centessa deal, Lilly is deepening its presence in neuroscience, building on a legacy that includes blockbuster treatments such as Prozac and more recent Alzheimer’s therapy Kisunla.
Centessa Pharmaceuticals PLC (NASDAQ:CNTA) shares are surging today, last seen 44.4% higher to trade at $39.90 on news that Eli Lilly (LLY) will acquire the company for $6.3 billion. The move is part of the former's plans to diversify its metabolic portfolio with sleep disorder treatments.
Analysts chimed in on the update, with Needham and B. Riley downgrading CNTA to "hold" and "neutral," respectively, from "buy." Piper Sandler cut its rating to "neutral" from "overweight." Analysts were bullish coming into today, with 16 of the 17 in coverage sporting "buy" or better ratings.
Options traders are targeting CNTA, too, with 3,467 calls and 2,687 puts traded so far -- 11 times the volume typically seen at this point. Most active is the April 30 call, followed by the December 22.50 puts.
CNTA is headed for its best day on record and earlier scored an all-time high of $40.26. The shares are staging a bounce off the rising 40-day moving average, and now sport a more than 203% nine-month lead.
Lilly to gain ownership of Centessa's OX2R agonist pipeline designed to improve outcomes across sleep-wake disordersCentessa’s OX2R agonist pipeline was jointly discovered by Nxera and Centessa, and Nxera retains a material economic interest in its future development and commercialization Tokyo, Japan and Cambridge, UK, 1 April 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that its partner, Centessa Pharmaceuticals Limited (“Centessa”), has announced that it entered into a definitive agreement regarding its acquisition by Eli Lilly and Company (“Lilly”) on 31 March 2026 (US local time).
Please refer to the full text of Centessa’s news release at the link below:
https://investors.centessa.com/press-releases/
Centessa's orexin receptor 2 (OX2R) agonist series, cleminorexton (formerly ORX750), ORX142 and ORX489, were jointly discovered by Centessa and Nxera scientists under a collaboration in which Centessa had access to Nxera's proprietary NxStaR™ technology. Nxera is entitled to receive certain milestone payments and royalties in relation to all of these OX2R agonists, and the contractual terms governing those rights are unaffected by this proposed transaction. In addition, Nxera holds an equity interest in Centessa.
Christopher Cargill, President and CEO of Nxera Pharma, commented: “We congratulate Centessa on its success to date advancing its OX2R agonist pipeline into clinical development and demonstrating best-in-class potential to bring improved outcomes to people with sleep-wake disorders. It will be exciting to see these novel candidates advance further under Lilly’s guidance.
“This is yet another example of a world-leading pharmaceutical company acquiring potential medicines with broad therapeutic application that originated in our research laboratory in Cambridge, United Kingdom, and a further demonstration of Nxera's rich heritage in CNS drug discovery. Potential medicines born from our NxStaR™ technology and NxWave™ GPCR structure-based drug design platform are now progressing toward late-stage clinical development with several of the world's leading pharmaceutical companies. The quality of our science, and the continued external validation of our platform, has never been stronger.
“We carry this momentum forward as we apply the same capabilities to our emerging, wholly owned metabolic and rare endocrine disease pipeline, targeting some of the largest areas of global unmet medical need. Nxera remains committed to delivering new treatment options to patients around the world through innovative science.”
Nxera has a separate multi-target collaboration with Lilly, entered in 2022, to leverage Nxera’s NxWave™ GPCR-focused structure-based drug design capabilities and Lilly’s extensive development, commercialization and therapeutic area expertise in metabolic diseases. The collaboration remains ongoing. Under the terms of that separate agreement, Nxera is eligible to receive development and commercial milestones totalling up to US$694 million, plus tiered royalties on global sales.
–END–
About Nxera Pharma
Nxera Pharma is a technology powered biopharma company in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally. The Company has built an agile, new-generation commercial business in Japan to develop and commercialize innovative medicines, including several launched products, to address this high-value, large and growing market and those in the broader APAC region. In addition, the Company is advancing an extensive pipeline internally and in partnership with leading pharma and biotech companies powered by its unique NxWave™ GPCR structure-based drug discovery platform. Nxera Pharma operates at key locations in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel (Switzerland) and Seoul (South Korea) and is listed on the Tokyo Stock Exchange (ticker: 4565).
For more information, please visit www.nxera.life
LinkedIn: @NxeraPharma | X: @NxeraPharma | YouTube: @NxeraPharma
Enquiries:
Nxera – Media and Investor Relations
Shinya Tsuzuki, VP, Head of Investor Relations
Maya Bennison, Communications Manager
+81 (0)3 5210 3399 | +44 (0)1223 949390 |[email protected]
MEDiSTRAVA (for International Media)
Mark Swallow, Frazer Hall, Erica Hollingsworth
+44 (0)203 928 6900 | [email protected]
Forward-looking statements
This press release contains forward-looking statements, including statements about the discovery, development, and commercialization of products. Various risks may cause Nxera Pharma Group’s actual results to differ materially from those expressed or implied by the forward looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Shares of Centessa Pharmaceuticals (CNTA 0.14%) surged on Tuesday after the drugmaker struck a deal to be acquired by Eli Lilly (LLY 0.51%) for as much as $7.8 billion.
Image source: Getty Images.
An enticing offer for Centessa's investors Under the terms of the deal, Lilly would purchase Centessa for $38 per share in cash. That's a premium of nearly 38% to the healthcare stock's closing price on Monday.
Centessa's shareholders would also receive a non-transferrable contingent value right, which could be valued at up to $9 per share if the pharmaceutical company's investigational drugs achieve certain regulatory milestones.
The transaction is projected to close in the third quarter, subject to shareholder and regulatory approval.
Today's Change
(
-0.14
%) $
-0.06
Current Price
$
39.70
Advancing neuroscience Centessa is developing a novel class of drugs, known as orexin receptor 2 (OX2R) agonists, to treat daytime sleepiness and other neurological conditions. Its most promising experimental drug, cleminorexton, showed best-in-class potential in Phase 2 clinical studies for severe sleep disorders, including narcolepsy and idiopathic hypersomnia.
"Orexin receptor biology represents one of the most compelling mechanistic opportunities in neuroscience as a direct intervention on the master switch of the sleep-wake cycle," Lilly executive Carole Ho said. "Centessa has assembled a portfolio with the breadth and depth to improve wakefulness across a broad array of indications."
Blockbuster potential Lilly is wisely using the windfall from its highly successful GLP-1 drugs Mounjaro and Zepbound to diversify its development pipeline. Centessa's experimental therapies could become top sellers in a potential $20 billion market for treatments for severe sleep conditions, according to investment bank Oppenheimer.
Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Centessa Pharmaceuticals Plc. The Motley Fool has a disclosure policy.
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Centessa Pharmaceuticals plc (NasdaqGS: CNTA) to Eli Lilly and Company (NYSE: LLY). Under the terms of the proposed transaction, shareholders of Centessa will receive $38.00 in cash per share plus one non-transferrable contingent value right entitling the holder to receive up to an aggregate of $9.00 subject to the achievement of certain milestones. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ([email protected]) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqgs-cnta/ to learn more.
To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.
Pre-Market Stock Futures: Futures are trading higher after an explosive rally on Tuesday, sparked by the President’s comments that he wants to end the war soon. While this is hardly the final straw for the war, it appears that President Trump, who is finally getting some support from NATO members and Persian Gulf allies in the fight against Iran and its paid proxies, may be making some progress. Add in the fact that Iran’s infrastructure and weaponry have been devastated, and many of the military and Revolutionary Guard leaders have been killed. Toss in the massive short interest, and it all adds up to Tuesday’s huge rally, with the Nasdaq as the big winner, closing up a stunning 3.83% at 21,590, and the small-cap Russell 2000 not far behind, finishing the session at 2,496, up 3.41%. The S&P 500 closed Tuesday at 6,528, up 2.91%, and the Dow Jones Industrial finished the clean sweep of winners, closing at 46,341, up 2.49%.
Treasury Bonds: Yields were lower across the curve, except at the very short T-bills and the long end, as buyers returned, as they did on Monday. Some of the same reasons we have cited recently for bond prices rising (and yields falling) were again driven by safe-haven demand amid intensified Middle East conflict. Investors shifted from fears of inflation to concerns about slower global growth, prompting a “bull steepening” of the yield curve and a rebound after a month of heavy selling.
Oil and Gas: Prices were mixed across the energy complex, which experienced severe intraday volatility, initially dropping on reports of a potential de-escalation in Iran but remaining supported by lingering anxieties over supply disruptions, particularly after a tanker was hit near Dubai. Toss in futures contract expirations, and the stage was set for a crazy end to the quarter. Brent Crude closed up 4.94% at $118.30, while West Texas Intermediate closed down at $101.50, down 1.33%. Natural Gas finished the day at $2.84, dowm 0.10%.
Gold: The precious metals joined in on the rally as gold, which has traded in a tight range for the better part of the first quarter, had an impressive day, closing trading up a whopping 3.49% at $4,667, while Silver really had some momentum buying and was last seen on Tuesday at $75, up a strong 7.18%. Wall Street analysts attributed the big moves higher to the recent decline to market overreaction, as investors moved to buy the dip. This rebound suggests a resilient bullish sentiment, even as the market grapples with rising oil prices, inflationary pressure, and weakening consumer confidence.
Crypto: The cryptocurrency market endured a turbulent session marked by sharp price swings but demonstrated solid resilience, holding firm at key support levels amid heightened geopolitical tensions. Developments heavily influenced risk sentiment across the broader crypto space, as traders responded swiftly to shifting headlines. Bitcoin led the volatility, surging to an intraday high of $68,300 in early trading after reports emerged of potential peace negotiations between Iran and Israel briefly lifted market optimism. However, the rally proved short-lived, with the crypto giant retracing to a consolidation range of $67,000–$67,800 as uncertainty resurfaced and profit-taking set in. The speed of the reversal underscored how sensitive the market remains to geopolitical developments, with algorithmic trading and leveraged positions amplifying the intraday swings. At 8 AM EDT, Bitcoin was trading at $68,680 while Ethereum was quoted at $2,135.
24/7 Wall St. reviews dozens of analyst research reports daily to identify new investment ideas for both investors and traders. Some of these daily analyst calls cover stocks to buy. Other calls cover stocks to sell or avoid. Remember that no single analyst call should ever be used as a basis to buy or sell a stock.
Here are some of the top Wall Street analyst upgrades, downgrades, and initiations seen on Wednesday, April 1, 2026.
Upgrades: Formula One Group (NASDAQ: FWONK | FWONK Price Prediction) was raised to Buy from Neutral at Bank of America, which has a $105 price target for the shares. Rivian Automotive Inc. (NASDAQ: RIVN) was upgraded to Neutral from Underperform at DA Davidson, with a $14 target price. United Health Group Inc. (NYSE: UNH) was upgraded to Outperform from Market Perform at Raymond James, which posted a $330 target price objective. Walt Disney Company (NYSE: DIS) was raised to Outperform from Market Perform at Raymond James, which has a $115 target for the entertainment giant. Wells Fargo & Company (NYSE: WFC) was upgraded to Buy from Hold at HSBC, with a $94 target price. Downgrades:
Apellis Pharmaceutical Inc. (NASDAQ: APLS) was downgraded to Hold from Buy at Stifel with a $41 target price as Biogen is acquiring the company. Centessa Pharmaceuticals Inc. (NASDAQ: CNTA) was downgraded to Market Perform from Outperform at Leerink, with a $40 target, as Eli Lilly is acquiring the company. First Citizens Bancshares Inc. (NASDAQ: FCNCA) was cut to Neutral from Overweight at JPMorgan, which dropped the target price for the shares to $2,200 from $2,450. Nike Inc. (NYSE: NKE) was downgraded to Neutral from Overweight at JPMorgan, which slashed the target price for the sports apparel and shoe giant to $52 from $86. PPG Industries Inc. (NYSE: PPG) was downgraded to Neutral from Buy at Citigroup, which trimmed the target price for the stock to $113 from $132. Initiations: Boeing Company (NYSE: BA) was initiated with an Overweight rating at Wells Fargo, which has a $250 target price for the aerospace giant.
Datadog Inc. (NASDAQ: DDOG) was started with a Buy rating at Benchmark, with a $150 target price. Northrop Grumman Corp. (NYSE: NOC) was started with an Overweight rating at Wells Fargo, with an $800 target price objective. Rocket Lab Corp. (NASDAQ: RKLB) was initiated with an Equal Weight rating at Wells Fargo, with a $60 target price. ServiceNow Inc. (NYSE: NOW) was initiated with a Buy rating at Benchmark with a $125 target price.
Key Takeaways Eli Lilly will buy Centessa for $6.3B upfront, with total value up to $7.8B including CVR payouts.LLY gains OX2R agonist pipeline, led by cleminorexton in mid-stage trials for narcolepsy and IH.Centessa surged 44% after the deal, which supports Lilly's broader pipeline diversification strategy. Eli Lilly (LLY - Free Report) announced that it has entered into a definitive agreement to acquire U.K.-based Centessa Pharmaceuticals (CNTA - Free Report) . Per the terms, the pharma giant will acquire all outstanding shares (including American Depositary Shares) of CNTA for $38 per share in cash, aggregating to about $6.3 billion.
In addition, Centessa’s shareholders will receive one non-tradable contingent value right (CVR) per share. This CVR entitles holders to an additional cash payment of up to $9 per share, contingent on achieving FDA approvals of either of its two pipeline drugs (cleminorexton and ORX142) across narcolepsy type II and idiopathic hypersomnia (IH) indications over the next few years. Including the CVR, the total potential deal value reaches approximately $7.8 billion.
Post this acquisition, Lilly will add Centessa’s pipeline of orexin receptor 2 (OX2R) agonists for treating people with sleep-wake disorders. This includes the lead drug, cleminorexton (formerly ORX750), which is being evaluated in a mid-stage study for two types of narcolepsy (type I and II) and IH. Last year, CNTA reported initial results from this study, which Lilly describes as demonstrating “a potential best-in-class profile” for the drug.
Another drug in Centessa’s pipeline is ORX142, which is being evaluated in an early-stage study for neurological and neurodegenerative disorders. A third candidate, ORX489, is currently in preclinical development and is being developed for neuropsychiatric disorders.
The transaction, which was approved by the board of directors of both companies, is expected to be closed in the third quarter.
CNTA & LLY Stock PerformanceFollowing this news on Tuesday, shares of Centessa increased 44%, while Lilly rose about 4%.
Year to date, CNTA stock has risen 59%, while that of LLY has lost more than 14%. During the same time frame, the industry has gained 1%.
Image Source: Zacks Investment Research
How Does CNTA Buyout Benefit LLY?Unlike some of its peers, such as Bristol Myers and Sanofi, which are under pressure from investors to pursue deals for new drugs, Lilly’s top line continues to reach new heights. The tremendous success of GLP-1 drugs, Mounjaro (for diabetes) and Zepbound (for obesity), has helped make it the first pharmaceutical company to reach a market capitalization of $1 trillion.
The rationale behind the deal is clear — Lilly intends to strategically diversify its pipeline across therapeutic areas. Recent approvals in immunology (Omvoh and Ebglyss), oncology (Jaypirca) and neuroscience (Kisunla) highlight Lilly’s intent to diversify beyond obesity and diabetes. A potential deal for Centessa fits this trend.
The transaction benefits CNTA, which lacks the commercial infrastructure and global scale required to bring advanced therapies to market, areas where LLY is already well established.
Once closed, this will be the third acquisition deal signed by Lilly so far this year. Earlier in January, it signed a $1.2 billion deal to buy Ventyx Biosciences to deepen its exposure to oral small-molecule therapies targeting inflammatory-mediated diseases. In February, LLY announced its intent to acquire Orna Therapeutics for up to $2.4 billion, which will add a broad portfolio of in vivo CAR-T pipeline.
Recent M&A Transactions in the Pharma SpaceWhile broader macroeconomic concerns — including Trump-era tariffs and leadership shifts at the FDA — have weighed on deal-making last year, Big Pharma continues to pursue strategic assets in key growth areas.
Recently, Biogen (BIIB - Free Report) announced its intent to acquire Apellis Pharmaceuticals for an upfront cash payment of about $5.6 billion to strengthen its immunology and rare disease portfolio. Through this transaction, BIIB intends to add two FDA-approved therapies — Empaveli and Syfovre. While Empaveli is approved for paroxysmal nocturnal hemoglobinuria (PNH) and two rare kidney diseases, Syforve is indicated for geographic atrophy. Biogen expects to close this deal in the second quarter of 2026.
Gilead Sciences (GILD - Free Report) is another company that has been involved in an acquisition spree since the start of this year. Last month, GILD entered into a deal worth $2.2 billion to acquire Ouro Medicines to strengthen its push into innovative therapies for autoimmune diseases. In February, Gilead announced its intent to acquire the clinical-stage biotechnology company Arcellx for an implied equity value worth $7.8 billion to boost its oncology portfolio.
These transactions highlight Big Pharma's continued interest in small biotechs with promising and innovative assets.
LLY & CNTA Zacks RankBoth Eli Lilly and Centessa Pharmaceuticals currently carry a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
, /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Centessa Pharmaceuticals plc (NASDAQ: CNTA) related to its sale to Eli Lilly and Company. Under the terms of the proposed transaction, Centessa shareholders are expected to receive $38.00 per share in cash and one non-transferable contingent value right entitling the holder to receive up to an aggregate of $9.00 subject to the achievement of certain milestones. Is it a fair deal?
Click here for more info https://monteverdelaw.com/case/centessa-pharmaceuticals-plc/. It is free and there is no cost or obligation to you.
NOT ALL LAW FIRMS ARE EQUAL. Before you hire a law firm, you should talk to a lawyer and ask:
Do you file class actions and go to Court? When was the last time you recovered money for shareholders? What cases did you recover money in and how much? About Monteverde & Associates PC
Our firm litigates and has recovered money for shareholders…and we do it from our offices in the Empire State Building. We are a national class action securities firm with a successful track record in trial and appellate courts, including the U.S. Supreme Court.
No one is above the law. If you own common stock in the above listed company and have concerns or wish to obtain additional information free of charge, please visit our website or contact Juan Monteverde, Esq. either via e-mail at [email protected] or by telephone at (212) 971-1341.
Contact:
Juan Monteverde, Esq.
MONTEVERDE & ASSOCIATES PC
The Empire State Building
350 Fifth Ave. Suite 4740
New York, NY 10118
United States of America
[email protected]
Tel: (212) 971-1341
Attorney Advertising. (C) 2026 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com). Prior results do not guarantee a similar outcome with respect to any future matter.
Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA – Get Free Report)’s stock price hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as $40.00 and last traded at $40.0980, with a volume of 3519760 shares trading hands. The stock had previously closed at $27.58.
Trending Headlines about Centessa Pharmaceuticals Here are the key news stories impacting Centessa Pharmaceuticals this week:
Positive Sentiment: Eli Lilly agreed to acquire Centessa in a deal worth up to $7.8 billion (initial $38.00/share cash plus contingent value rights), which creates a takeover premium and is the primary driver of the stock’s upward move. Eli Lilly to buy Centessa Pharma Positive Sentiment: Leerink Partners reaffirmed a “market perform” rating and raised its price target to $40.00, a small upward revision that supports the view the deal price is appropriate. Leerink raises price target Neutral Sentiment: Unusual options activity: earlier spikes in call buying and, more recently, a large surge in put purchases (10,659 puts) signal mixed positioning—some traders betting on deal completion/arb, others hedging or speculating on downside. (No single article link) Negative Sentiment: Multiple brokerages downgraded CNTA (Needham, Wolfe Research, Stephens), citing valuation or deal-related uncertainty — analyst downgrades can weigh on momentum despite the takeover premium. Needham downgrades Negative Sentiment: Several law firms and shareholder groups have announced investigations into whether the sale process and price are fair (Monteverde, Kahn Swick & Foti, Ademi, Halper Sadeh). Potential litigation or challenges to the transaction could delay closing or pressure the spread between market price and deal consideration. Shareholder investigation announced Negative Sentiment: Recent quarterly results missed EPS estimates (reported ($0.48) vs. consensus ($0.38)), underscoring ongoing clinical and execution risks outside the transaction context. Centessa earnings miss Wall Street Analyst Weigh In Several research firms recently commented on CNTA. Stephens cut Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday. Truist Financial boosted their price target on Centessa Pharmaceuticals from $33.00 to $38.00 and gave the company a “buy” rating in a research note on Thursday, January 29th. TD Cowen restated a “buy” rating on shares of Centessa Pharmaceuticals in a report on Wednesday, January 14th. Piper Sandler reaffirmed an “overweight” rating on shares of Centessa Pharmaceuticals in a research report on Friday, January 16th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a research report on Wednesday, January 21st. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $40.00.
Read Our Latest Analysis on CNTA
Centessa Pharmaceuticals Stock Performance The company has a market capitalization of $5.82 billion, a price-to-earnings ratio of -21.78 and a beta of 1.25. The company has a 50 day moving average price of $26.62 and a 200 day moving average price of $25.35. The company has a debt-to-equity ratio of 0.36, a quick ratio of 10.57 and a current ratio of 10.56.
Centessa Pharmaceuticals (NASDAQ:CNTA – Get Free Report) last announced its quarterly earnings results on Monday, April 6th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.10). Equities research analysts predict that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 earnings per share for the current fiscal year.
Insider Transactions at Centessa Pharmaceuticals In related news, insider Gregory M. Weinhoff sold 73,196 shares of the stock in a transaction on Friday, March 13th. The stock was sold at an average price of $26.33, for a total value of $1,927,250.68. Following the transaction, the insider directly owned 65,925 shares in the company, valued at $1,735,805.25. This trade represents a 52.61% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Karen M. Anderson sold 120,029 shares of Centessa Pharmaceuticals stock in a transaction on Friday, March 13th. The shares were sold at an average price of $26.25, for a total transaction of $3,150,761.25. Following the completion of the sale, the insider directly owned 62,085 shares of the company’s stock, valued at approximately $1,629,731.25. The trade was a 65.91% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 349,073 shares of company stock valued at $9,429,412 over the last ninety days. 7.09% of the stock is owned by company insiders.
Institutional Inflows and Outflows A number of hedge funds have recently made changes to their positions in the business. Avoro Capital Advisors LLC increased its position in shares of Centessa Pharmaceuticals by 116.2% during the third quarter. Avoro Capital Advisors LLC now owns 10,808,080 shares of the company’s stock worth $262,096,000 after acquiring an additional 5,808,080 shares in the last quarter. EcoR1 Capital LLC lifted its position in Centessa Pharmaceuticals by 466.4% in the 4th quarter. EcoR1 Capital LLC now owns 3,115,000 shares of the company’s stock valued at $77,906,000 after acquiring an additional 2,565,000 shares in the last quarter. Braidwell LP bought a new position in Centessa Pharmaceuticals in the 4th quarter valued at about $54,730,000. Federated Hermes Inc. acquired a new position in Centessa Pharmaceuticals during the 3rd quarter valued at about $42,429,000. Finally, Maverick Capital Ltd. acquired a new position in Centessa Pharmaceuticals during the 4th quarter valued at about $41,110,000. 82.01% of the stock is currently owned by institutional investors and hedge funds.
Centessa Pharmaceuticals Company Profile (Get Free Report)
Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.
Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.
Recommended Stories Five stocks we like better than Centessa Pharmaceuticals Receive News & Ratings for Centessa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centessa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEHoneywell International Inc. (NASDAQ:HON) Sees Large Growth in Short Interest
NEXT HEADLINE »Short Interest in S&P Global Inc. (NYSE:SPGI) Declines By 15.1%
MILWAUKEE, April 07, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Centessa (NASDAQ: CNTA) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Lilly.
Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you.
In the transaction, Centessa stockholders will receive $38.00 per share in cash plus contingent value rights worth up to $9.00 per share. The contingent value rights entitle holders to receive up to three milestone payments: $2.00 upon U.S. FDA approval for narcolepsy type 2 treatment, $5.00 for idiopathic hypersomnia approval, and $2.00 for any indication approval before January 1, 2030. All approvals must occur within five years of transaction closing.
Centessa insiders will receive substantial benefits as part of change of control arrangements.
The transaction agreement unreasonably limits competing transactions for Centessa by imposing a significant penalty if Centessa accepts a competing bid. We are investigating the conduct of the Centessa board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.
We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.
The proposed transactions may contain terms that could limit superior competing offers.
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
, /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)'s sale to Biogen Inc. for $41.00 per share in cash and a nontransferable contingent value right for the right to receive two payments of $2.00 per share each, contingent on certain annual global net sales thresholds being met for SYFOVRE. If you are an Apellis shareholder, click here to learn more about your legal rights and options.
Centessa Pharmaceuticals plc (NASDAQ: CNTA)'s sale to Eli Lilly and Company for $38.00 in cash per share plus one non-transferrable contingent value right entitling the holder to receive up to an aggregate of $9.00 subject to the achievement of certain milestones. If you are a Centessa shareholder, click here to learn more about your legal rights and options.
Kezar Life Sciences, Inc. (NASDAQ: KZR)'s sale to Aurinia Pharmaceuticals Inc. for $6.955 in cash per share and one non-transferable contingent value right. If you are a Kezar shareholder, click here to learn more about your legal rights and options.
On behalf of shareholders, Halper Sadeh LLC may seek increased consideration, additional disclosures and information, or other relief and benefits.
Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Halper Sadeh LLC
Daniel Sadeh, Esq.
Zachary Halper, Esq.
One World Trade Center
85th Floor
New York, NY 10007
(212) 763-0060
[email protected]
[email protected]
https://www.halpersadeh.com
Pre-Market Stock Futures: Futures are trading lower this morning after negotiations with Iran failed over the weekend, and President Trump indicated the U.S. will block the Strait of Hormuz. This comes as we get set to start the first-quarter earnings season this week, as the major money-center banks and brokerage firms begin to report results today and tomorrow. The stock market ended last week higher, but it was a grind, with big swings throughout. When trading ended Friday, the market posted its best week since November. All the major indices finished Friday lower, except the Nasdaq, which closed at 22,902, up 0.35%. The Dow Jones Industrials were the loss leader on Friday, closing down 0.56% to finish at 47,916, while the Russell 2000 was last seen at 2,630, down 0.22%. The venerable S&P 500 almost broke even by the close, finishing Friday’s session down just 0.11% at 6,816.
Treasury Bonds: After a solid week for the Treasury market, sellers returned on Friday as yields rose across the entire curve, driven by persistent worries about inflation and perceived growing geopolitical instability in the Middle East, with oil-driven inflation fears continuing to pressure the market. Markets are adjusting to a more hawkish Federal Reserve, as traders price in higher interest rates that lower the value of existing bonds. Plus, there is a major issue for the bond market, given the mounting inflation in recent reports, that there could be no interest rate cuts in 2026. The 30-year-long bond closed Friday at 4.91%, while the benchmark 10-year note closed at 4.32%.
Oil and Gas: After a wild week across the energy complex, oil finished in positive territory for consumers, as both major benchmarks finished lower on the day, trading below the pivotal and psychological $100 level. Brent Crude closed Friday at $94.29, down 1.60%, while West Texas Intermediate finished the week at $96.57, down 1.33%. Natural gas also finished the day and the week lower, closing at $2.65, down 0.82%.
Gold: The precious metals complex, like all the other major sectors, finished a volatile week on a quieter note on Friday. Gold closed the session at $4,747, down 0.38%, while Silver closed modestly higher at $75.76, up 0.55%.
Crypto: Crypto markets traded in a “risk-off” mode on Friday, with Bitcoin holding above $72,000 as investors braced for inflation data that came in higher than expected. The market saw a tentative recovery following a broader corrective phase, with Ethereum holding just above key support levels while trading above the 50-day exponential moving average. The Cryptocurrency arena remains fragile and cautious as market participants analyze March’s hot Consumer Price Index (CPI) data, which indicated mounting inflationary pressure. At 7 AM EDT, Bitcoin was trading at $70,825, while Ethereum was quoted at $2, 184.
24/7 Wall St. reviews dozens of analyst research reports daily to identify new investment ideas for both investors and traders. Some of these daily analyst calls cover stocks to buy. Other calls cover stocks to sell or avoid. Remember that no single analyst call should ever be used as a basis to buy or sell a stock.
Here are some of the top Wall Street analyst upgrades, downgrades, and initiations seen on Monday, April 13, 2026.
Upgrades: Bilibili Inc. (NASDAQ: BILI) | BILI Price Prediction was upgraded to Overweight from Equal Weight at Morgan Stanley, which raised the target price to $31 from $25. Constellation Brands Inc. (NYSE: STZ) was upgraded to Buy from Hold at TD Cowen, which raised the price target for the stock to $190 from $142. CoreWeave (NASDAQ: CRWV) was upgraded by Macquerie to Outperform from Neutral, which raised the target price for the stock to $125 from $90. Starbucks Corp. (NASDAQ: SBUX) was raised to Hold from Underperform at Jefferies, which boosted the target price for the ubiquitous coffee retailer to $92 from $86. T-Mobile US Inc. (NASDAQ: TMUS) was upgraded to Overweight from Sector Weight at KeyBanc, with a $260 target price objective. Downgrades: Best Buy Inc. (NYSE: BBY) was double downgraded to Sell from Buy at Goldman Sachs, which lowered the price target for the retailer to $59 from $76. Centessa Pharmaceuticals Inc. (NASDAQ: CNTA) was downgraded to Hold from Buy at Truist with a $38 target price. This is the amount Eli Lilly is paying to purchase the company. Hewlett Packard Enterprise Co. (NYSE: HPE) was downgraded to Outperform from Strong Buy at Raymond James, which trimmed the target price for the legacy tech giant to $29 from $30. Nebius Group NV (NASDAQ: NBIS) was downgraded to Hold from Buy at Freedom Capital, which raised the target price for the stock to $154 from $108. Nike Inc. (NYSE: NKE) was downgraded to Hold from Buy at HSBC, which slashed the target price for the sporting apparel and shoe giant to to $48 from $90. Initiations: Adobe Inc. (NASDAQ: ADBE) was initiated with a Neutral rating at BTIG, with no price target posted.
Credo Technology Group Holding Ltd. (NASDAQ: CRDO) was initiated with a Buy rating at Jefferies, which has set a $175 target price for the company. Johnson Controls Inc. (NYSE: JCI) was initiated with an In Line rating at Evercore ISI, with a $155 target price. Rollins Inc. (NYSE: ROL) was started with a Hold rating at Loop Capital, which has set a $56 target price for the shares. Tempus AI Inc. (NASDAQ: TEM) was started with an Underperform rating at Jefferies, with a $35 price target.
B. Metzler seel. Sohn & Co. AG purchased a new position in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA – Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 38,432 shares of the company’s stock, valued at approximately $961,000.
A number of other large investors also recently added to or reduced their stakes in CNTA. TD Waterhouse Canada Inc. purchased a new position in Centessa Pharmaceuticals in the 4th quarter worth approximately $25,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Centessa Pharmaceuticals by 26.4% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,688 shares of the company’s stock worth $117,000 after purchasing an additional 979 shares in the last quarter. DNB Asset Management AS purchased a new position in Centessa Pharmaceuticals in the 3rd quarter worth approximately $218,000. GSA Capital Partners LLP purchased a new position in Centessa Pharmaceuticals in the 3rd quarter worth approximately $455,000. Finally, BNP Paribas Financial Markets lifted its holdings in Centessa Pharmaceuticals by 3,028.1% in the 2nd quarter. BNP Paribas Financial Markets now owns 34,972 shares of the company’s stock worth $460,000 after purchasing an additional 33,854 shares in the last quarter. 82.01% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes A number of research firms recently commented on CNTA. Stephens cut Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, March 31st. Leerink Partners downgraded Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating and lifted their price objective for the stock from $36.00 to $40.00 in a research note on Wednesday, April 1st. B. Riley Financial downgraded Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, March 31st. Chardan Capital reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Centessa Pharmaceuticals in a research note on Friday, January 2nd. Finally, Lifesci Capital downgraded Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 1st. Four analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Centessa Pharmaceuticals has an average rating of “Hold” and an average target price of $40.70.
Read Our Latest Analysis on Centessa Pharmaceuticals
Centessa Pharmaceuticals Stock Performance NASDAQ:CNTA opened at $39.47 on Monday. The company has a debt-to-equity ratio of 0.21, a current ratio of 8.57 and a quick ratio of 8.57. Centessa Pharmaceuticals PLC Sponsored ADR has a 1 year low of $10.95 and a 1 year high of $40.26. The stock’s 50 day simple moving average is $31.71 and its two-hundred day simple moving average is $27.35. The company has a market cap of $5.89 billion, a price-to-earnings ratio of -26.85 and a beta of 1.25.
Centessa Pharmaceuticals (NASDAQ:CNTA – Get Free Report) last released its quarterly earnings data on Tuesday, March 31st. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.10). As a group, equities analysts anticipate that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.65 earnings per share for the current fiscal year.
Insider Activity In other news, insider Iqbal J. Hussain sold 38,951 shares of the business’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $25.15, for a total transaction of $979,617.65. Following the transaction, the insider owned 57,645 shares of the company’s stock, valued at approximately $1,449,771.75. The trade was a 40.32% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Gregory M. Weinhoff sold 73,196 shares of the business’s stock in a transaction that occurred on Friday, March 13th. The shares were sold at an average price of $26.33, for a total value of $1,927,250.68. Following the transaction, the insider directly owned 65,925 shares in the company, valued at approximately $1,735,805.25. This represents a 52.61% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 349,073 shares of company stock valued at $9,429,412. 7.09% of the stock is currently owned by insiders.
About Centessa Pharmaceuticals (Free Report)
Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.
Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.
Featured Articles Five stocks we like better than Centessa Pharmaceuticals Want to see what other hedge funds are holding CNTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA – Free Report).
Receive News & Ratings for Centessa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centessa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEDycom Industries, Inc. $DY Shares Sold by B. Metzler seel. Sohn & Co. AG
NEXT HEADLINE »Farther Finance Advisors LLC Takes $500,000 Position in United States Gasoline Fund LP $UGA
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Centessa Pharmaceuticals plc (NasdaqGS: CNTA) to Eli Lilly and Company (NYSE: LLY). Under the terms of the proposed transaction, shareholders of Centessa will receive $38.00 in cash per share plus one non-transferrable contingent value right entitling the holder to receive up to an aggregate of $9.00 subject to the achievement of certain milestones. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ([email protected]) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqgs-cnta/ to learn more.
To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.
The proposed transactions may contain terms that could limit superior competing offers.
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
, /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Centessa Pharmaceuticals plc (NASDAQ: CNTA)'s sale to Eli Lilly and Company for $38.00 in cash per share plus one non-transferrable contingent value right entitling the holder to receive up to an aggregate of $9.00 subject to the achievement of certain milestones. If you are a Centessa shareholder, click here to learn more about your legal rights and options.
Whitestone REIT (NYSE: WSR)'s sale to Ares Management Corporation for $19.00 per share or unit. If you are a Whitestone shareholder, click here to learn more about your legal rights and options.
Green Dot Corporation (NYSE: GDOT)'s sale to Smith Ventures and CommerceOne Financial Corporation for $8.11 in cash and 0.2215 shares of a new publicly traded bank holding company for each share of Green Dot. If you are a Green Dot shareholder, click here to learn more about your rights and options.
On behalf of shareholders, Halper Sadeh LLC may seek increased consideration, additional disclosures and information, or other relief and benefits.
Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Halper Sadeh LLC
Daniel Sadeh, Esq.
Zachary Halper, Esq.
One World Trade Center
85th Floor
New York, NY 10007
(212) 763-0060
[email protected]
[email protected]
https://www.halpersadeh.com
Proven Chief Medical Officer at several publicly listed and clinical-stage oncology companies with successful track record developing multiple modalities including radiotherapies from preclinical through global approvals across hematologic malignancies and solid tumors Played a leading role in clinical development and worldwide approvals of Erbitux® at Merck KGaA leading to its blockbuster status Led clinical development as CMO of NBE Therapeutics which was acquired by Boehringer Ingelheim for $1.4 billion, and most recently CMO of radiotherapy company Full-Life Technologies Timely key hire with Dr. Heeger's operational rigor and clinical expertise expected to elevate development of Actimab-A, ATNM-400, and Iomab-ACT as Actinium advances toward key data readouts and expanded clinical trials in 2H:2026 , /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced the appointment of Steffen Heeger, MD, MSc, as Chief Medical Officer. Dr. Heeger brings a rare combination of radiotherapy expertise, global oncology drug development leadership, and public-company experience. Over his career, he has translated multiple programs from IND submission through global clinical approval in the US, EU, and Japan including the blockbuster Erbitux® and led as CMO an oncology company acquired for $1.4 billion. Most recently Dr. Heeger served as CMO of a clinical-stage radiotherapy company where he advanced into global development, a PSMA program directly relevant to Actinium's ATNM-400 asset. His appointment comes at a pivotal moment as Actinium prepares to advance Actimab-A, ATNM-400, and Iomab-ACT toward key data readouts and expanded clinical trials in the second half of 2026.
"Steffen's background is uniquely suited to unlock the value in Actinium's pipeline" said Sandesh Seth, Chairman and Chief Executive Officer of Actinium Pharmaceuticals. "He has successfully taken multiple targeted oncology and radiotherapy programs from the lab into patients, including anti-PSMA programs directly relevant to our ATNM-400 asset, and has deep experience navigating global regulatory pathways with the FDA and international agencies. Steffen brings precisely the combination of deep radiotherapy expertise, global oncology clinical development leadership, regulatory experience, and executional intensity that we need as we advance and expand our pipeline of targeted radiotherapies."
"Importantly, Steffen's experience spans both hematologic malignancies and solid tumors, aligning exceptionally well with our strategic focus of building Actinium into a leading targeted radiotherapy company." Mr. Seth added. "His direct experience with alpha-emitting radiotherapies, translational medicine, and global clinical execution will be highly valuable as we progress our clinical programs and pursue new opportunities to unlock the full potential of our platform. Few clinical leaders know radiotherapy development as deeply as Steffen does, and fewer still pair that with the public-company experience and translational oncology track record he brings. We are thrilled to welcome him to Actinium."
Prior to Actinium, Dr. Heeger served as Chief Medical Officer of Full-Life Technologies, where he led global development, regulatory affairs, clinical operations, translational research, CMC, quality assurance, and program management for the company's radiotherapy pipeline. There he led the translation of three targeted radioconjugate compounds — including an anti-PSMA program in metastatic castration-resistant prostate cancer — from preclinical to clinical stage within two years, securing IND clearance and fast track designation. Prior to Full-Life, he was CMO of Pega-One, a clinical-stage oncology company that became part of Centessa Pharmaceuticals (Nasdaq: CNTA) ahead of its $380 million initial public offering. Earlier, he served as CMO of NBE-Therapeutics, where he led the IND submission and initial clinical trial of NBE-002, a first-in-class immune-stimulatory antibody-drug conjugate targeting ROR1 in triple-negative breast cancer, non-small cell lung cancer, and sarcoma. NBE-Therapeutics was subsequently acquired by Boehringer Ingelheim for $1.4 billion. Before NBE, Dr. Heeger was CMO of Selvita S.A. (WSE: SLV), where he advanced the company's lead anti-cancer compound through IND and into its first clinical trial.
Earlier in his career, Dr. Heeger served as Vice President, Head of Clinical Development at MorphoSys AG, where he led the clinical strategy and execution of the company's lead hematology and oncology programs, including monoclonal antibody therapeutics targeting CD19, CD38, and PSMA. He began his pharmaceutical career at Merck KGaA, where over nearly a decade, he led global clinical development and life cycle management for Erbitux® (cetuximab) across colorectal, head and neck, gastric, and lung cancers in major markets including the US, Europe, Japan, and China enabling its blockbuster status.
"Actinium is developing what I believe is one of the most compelling radiotherapy pipelines today." said Dr. Heeger. "Their biology-driven R&D has yielded several highly differentiated, even unique, assets that offer real opportunity to bring transformative therapies to patients with limited options. Their assets have nothing comparable being developed and each has blockbuster potential; ATNM-400 with its novel target and compelling data across the largest solid tumor indications, Actimab-A's promise to resensitize immune checkpoint inhibitors in solid tumors and backbone potential in hematological malignancies, as well as their cell and gene therapy conditioning agent Iomab-ACT. These are exactly the kinds of assets I have spent my career developing. I am honored to join Actinium at this pivotal stage and look forward to working closely with Sandesh and our team to unlock the value in our clinical programs."
Dr. Heeger holds an MD and a Master of Healthcare Management (MSc) from the University of Heidelberg, Germany, a world-leading institution for research in nuclear medicine and targeted radionuclide therapies. He trained as a clinical oncologist at the University Hospital Heidelberg, Department of Haematology and Oncology, and at the German Cancer Research Center. He has authored and co-authored more than 20 peer-reviewed publications across oncology and radiopharmaceutical research. Notably, Dr. Heeger's scientific roots include early work in alpha-radiotherapy, including published research involving alpha-radioimmunotherapy using antibody conjugates in hematologic malignancies which bring him to a full cycle at Actinium.
About Actinium Pharmaceuticals, Inc.
Actinium is a pioneer in targeted radiotherapies designed to improve outcomes for patients with cancer. The company employs a biology-driven approach to develop differentiated radiopharmaceuticals for solid tumors and hematologic malignancies. Its mission is to transform cancer treatment through innovative radioconjugates that maximize therapeutic efficacy while minimizing toxicity to healthy tissue by combining expertise in tumor biology, translational medicine, and radiochemistry. Since inception, Actinium has focused on developing innovative radiotherapies. Its pipeline reflects this strategy across three areas: (1) solid tumor therapeutics including ATNM-400 and Actimab-A with pan-tumor potential; (2) Actimab-A as a therapeutic backbone for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in collaboration with the National Cancer Institute (NCI); and (3) targeted conditioning agents including Iomab-B for bone marrow transplant and Iomab-ACT for cell and gene therapy conditioning. ATNM-400 targets a novel antigen distinct from PSMA and has demonstrated preclinical activity across metastatic castration-resistant prostate cancer (mCRPC), non-small cell lung cancer (NSCLC), and breast cancer. Actimab-A has shown improved survival in relapsed/refractory AML with CLAG-M and is advancing toward a Phase 2/3 trial, with additional development ongoing through a CRADA with the NCI. Actinium is also advancing preclinical solid tumor programs and holds ~250 patents and patent applications, including intellectual property related to cyclotron-based production of Ac-225. For more information, please visit www.actiniumpharma.com.
Forward-Looking Statements
This press release may contain projections or other "forward-looking statements" within the meaning of the "safe-harbor" provisions of the private securities litigation reform act of 1995 regarding future events or the future financial performance of the Company which the Company undertakes no obligation to update. These statements, including statements as related to regaining compliance with the rules of the NYSE American and submission of a compliance plan, are based on management's current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with preliminary study results varying from final results, estimates of potential markets for drugs under development, clinical trials, actions by the FDA and other governmental agencies, regulatory clearances, responses to regulatory matters, the market demand for and acceptance of Actinium's products and services, performance of clinical research organizations and other risks detailed from time to time in Actinium's filings with the Securities and Exchange Commission (the "SEC"), including without limitation its most recent annual report on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms 8-K, each as amended and supplemented from time to time.
Alstom will deliver a fully integrated, turnkey metro solution, including 32 Metropolis trainsThis flagship urban project valued at €915 million[1] will support Serbia’s long-term growth, connectivity and climate ambitions 27 March 2026 – Alstom, a global leader in smart and sustainable mobility, has secured a €915 million turnkey contract to deliver Belgrade’s Metro Line 1, the first fully automated metro system in Serbia. This project, connecting in the first phase Makiško Polje to Karaburma will alleviate surface congestion and unlock Belgrade’s potential as a leading European capital city.
By cutting directly through the city center, the first phase of Metro Line 1 will span 15 km and 15 stations, including 11 km of tunnels. This is a structural transformation: by moving a significant portion of the city’s transit underground, the project will alleviate chronic surface congestion and unlock Belgrade’s potential as a more accessible, functional European capital. The introduction of one of the world's most modern automated systems will serve as a multiplier for the city's economic attractiveness, creating a more efficient environment for both residents and international investment.
“Belgrade’s decision to build its first fully automated metro is a pragmatic and bold investment in the city’s future and it reflects the strong leadership and vision demonstrated by the Serbian authorities” said Andrew DeLeone, President of Alstom Europe. “Metro Line 1 will fundamentally change how nearly two million residents navigate their city, providing a reliable and safe alternative to road transit. This project is not just about mobility; it is about delivering the modern infrastructure necessary for Belgrade to sustain its growth and meet its long-term economic and climate objectives”.
In this project for the public utility company, Belgrade Metro & Train, Alstom, as system integrator will deliver a full turnkey metro solution, including 32 Metropolis driverless three-car trains, signaling and telecommunications, power supply, trackwork, platform screen doors, depot equipment, a centralized control center, and comprehensive cybersecurity systems. The metro will be equipped with Alstom’s advanced Urbalis CBTC technology, enabling fully automated, high-capacity and reliable operations. The Metropolis trains will be manufactured at Alstom’s Valenciennes site in France.
The project benefits from French government funding support, underlining the strong bilateral cooperation between France and Serbia. Alstom has now officially entered the design phase for Metro Line 1.
The introduction of driverless metro technology will bring tangible benefits, including increased frequency, higher passenger capacity, improved operational resilience and enhanced safety. The turnkey system will enable reliable, energy-efficient operations, with headways of up to 90 seconds, supported by a state-of-the-art integrated control center and cybersecurity platform.
Alstom is a pioneer in automated metro systems, with nearly 30 driverless lines in operation worldwide, including in Paris, Singapore and Lyon. With more than 50 years of experience and 80 turnkey systems in commercial service worldwide, Alstom is a trusted partner for complex metro projects. Recent references include Montreal REM, Riyadh Metro, Athens Line 4, Grand Paris Line 18, Toulouse Line C, Panama Line 2, Guadalajara Line 3 and Dubai Metro Route 2020.
ALSTOM™, Metropolis™ and Urbalis™ are protected trademarks of the Alstom Group.
About Alstom
Alstom is the pure rail leader, committed to making rail the backbone of sustainable transportation. We design and deliver a complete range of future-ready solutions – from high-speed and regional trains to metros, monorails, trams, turnkey systems, end-to-end services, infrastructure, signalling and digital rail solutions. With 86,000 people in 63 countries, Alstom brings together global expertise and multi-local presence to make every journey smarter, cleaner and more enjoyable. Together with our partners and customers, we realise the power of rail. Listed in France, Alstom generated revenues of €18.5 billion for the fiscal year ending 31 March 2025.
For more information, please visit www.alstom.com.
31 March 2026 – Alstom, a global leader in smart and sustainable mobility, is pleased to announce that it has signed a new systems contract in the AMECA region, as part of a consortium, with a total project value of USD 2.75 billion. Alstom’s share represents approximately 30% of the total contract value, corresponding to approximately EUR 700 million.
This order has been recorded in Alstom’s Q4 2025/2026 fiscal year.
Alstom™ is a protected trademark of the Alstom Group.
About Alstom Alstom commits to contribute to a low carbon future by developing and promoting innovative and sustainable transportation solutions that people enjoy riding. From high-speed trains, metros, monorails, trams, to turnkey systems, services, infrastructure, signalling and digital mobility, Alstom offers its diverse customers the broadest portfolio in the industry. With its presence in 63 countries and a talent base of over 86,000 people from 184 nationalities, the company focuses its design, innovation, and project management skills to where mobility solutions are needed most. Listed in France, Alstom generated sales of €18.5 billion for the fiscal year ending on 31 March 2025.
For more information, please visit www.alstom.com. ContactsPress
Coralie COLLET - Tel.: +33 (0) 7 63 63 09 62 [email protected] BEKHTI –Tel.: +971 56 995 45 76
A logo on the side of a building at the Alstom train works in Derby, Britain, October 27, 2025. REUTERS/Phil Noble Purchase Licensing Rights, opens new tab
CompaniesApril 1 (Reuters) - Alstom (ALSO.PA), opens new tab has appointed Martin Sion as its new chief executive officer with immediate effect, the French train maker said on Wednesday.
Former CEO Henri Poupart-Lafarge has decided not to seek a further term after a decade at the head of Alstom, the company said in the statement.
Stay up to date on the key companies, data, and decisions in the ESG world with the Reuters Sustainable Finance newsletter. Sign up here.
Sion joins the group with an engineering background and after three years as the CEO of space and defense company ArianeGroup, equally owned by Airbus (AIR.PA), opens new tab and Safran (SAF.PA), opens new tab.
Under his leadership, Europe's new-generation Ariane 6 launcher, developed by ArianeGroup and the European Space Agency, started its first missions in a context of increased competition from SpaceX and Boeing (BA.N), opens new tab.
Reporting by Mathias de Rozario in Gdansk, editing by Milla Nissi-Prussak
Our Standards: The Thomson Reuters Trust Principles., opens new tab
08 April 2026 – Alstom, a global leader in smart and sustainable mobility, is pleased to announce that it has received a Signalling contract in the Europe region for approximately €295 million.
This order was booked in Alstom’s Q4 2025/2026 fiscal year.
Alstom™ is a protected trademark of the Alstom Group.
About Alstom Alstom is the pure rail leader, committed to making rail the backbone of sustainable transportation. We design and deliver a
complete range of future-ready solutions – from high-speed and regional trains to metros, monorails, trams, turnkey systems,
end-to-end services, infrastructure, signalling and digital rail solutions. With 86,000 people in 63 countries, Alstom brings
together global expertise and multi-local presence to make every journey smarter, cleaner and more enjoyable. Together with
our partners and customers, we realise the power of rail. Listed in France, Alstom generated revenues of €18.5 billion for the
fiscal year ending 31 March 2025.
For more information, please visit www.alstom.com. ContactsPress
Coralie COLLET - Tel.: +33 (0) 7 63 63 09 62 [email protected] Relations
Cyril GUERIN - Tel.: +33 (0)6 07 89 36 16 [email protected]
Alstom experienced a 20%+ single-day drop after withdrawing FCF guidance and warning on profits, triggering a major revaluation. Despite record orders and a €100B+ backlog, ALSMY faces execution challenges, margin pressure, and recurring operational issues impacting earnings visibility. I view the market reaction as an overreaction; at sub-€17/share, ALSMY trades below 10x P/E, presenting long-term value despite historical volatility.
SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Alstom S.A. (OTC: ALSMY; AOMFF). The investigation focuses on Alstom’s executive officers and whether investor losses may be recovered under federal securities laws.
What if I purchased Alstom securities?
If you purchased Alstom securities and suffered losses on your investment, join our investigation now: Click here to join the investigation.
Or for more information, contact Jim Baker at [email protected] or (619) 814-4471.
There is no cost or obligation to you.
Background of the investigation
On April 16, 2026, Alstom S.A. announced preliminary unaudited results for the fiscal year ended March 31, 2026. Among other things, the Company disclosed that it manufactured 4,284 cars during the fiscal year and that adjusted EBIT margin stood at around 6%.
The Company further stated that “some large rolling-stock projects have progressed more slowly than anticipated,” weighing on near-term margins and cash. In addition, Alstom disclosed free cash flow of approximately €330 million, withdrew its three-year cumulative €1.5 billion free cash flow guidance, and stated that its prior medium-term ambition of adjusted EBIT margin of 8–10% would no longer be met by the end of its next fiscal year.
Following this disclosure, the price of Alstom’s stock declined sharply, damaging investors.
In light of this disclosure, Johnson Fistel is investigating whether Alstom complied with the federal securities laws. If you suffered losses from your investment in Alstom stock, contact Johnson Fistel.
About Johnson Fistel, PLLP | Securities Fraud & Investor Rights
Johnson Fistel, PLLP is a nationally recognized shareholder-rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits and also assists foreign investors who purchased shares on U.S. exchanges. To learn more, visit www.johnsonfistel.com.
Achievements
In 2024, Johnson Fistel was ranked among the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services, reflecting the firm’s effectiveness in advocating for investors and recovering approximately $90,725,000 for clients in cases where it served as lead or co-lead counsel.
Attorney advertising.
Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.
Johnson Fistel, PLLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.
Contact
Johnson Fistel, PLLP
501 W. Broadway, Suite 800
San Diego, CA 92101
James Baker, Investor Relations – or – Frank J. Johnson, Esq.
(619) 814-4471 | [email protected] | [email protected]
NEW YORK, April 28, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Alstom S.A. (“Alstom” or the “Company”) (OTCMKTS: ALSMY; AOMFF). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Alstom and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On April 16, 2026, Alstom S.A. announced preliminary unaudited results for the fiscal year ended March 31, 2026. Among other things, the Company disclosed that it manufactured 4,284 cars during the fiscal year and that adjusted EBIT margin stood at around 6%. The Company further disclosed that “some large rolling-stock projects have progressed more slowly than anticipated,” weighing on near-term margins and cash. In addition, Alstom disclosed free cash flow of approximately €330 million, withdrew its three-year cumulative €1.5 billion free cash flow guidance, and said that its prior medium-term ambition of adjusted EBIT margin of 8-10% would no longer be met by the end of its next fiscal year.
Following these disclosures, Alstom’s stock price fell sharply, damaging investors.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Alstom S.A. ("Alstom" or the "Company") (OTCMKTS: ALSMY; AOMFF). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Alstom and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On April 16, 2026, Alstom S.A. announced preliminary unaudited results for the fiscal year ended March 31, 2026. Among other things, the Company disclosed that it manufactured 4,284 cars during the fiscal year and that adjusted EBIT margin stood at around 6%. The Company further disclosed that "some large rolling-stock projects have progressed more slowly than anticipated," weighing on near-term margins and cash. In addition, Alstom disclosed free cash flow of approximately €330 million, withdrew its three-year cumulative €1.5 billion free cash flow guidance, and said that its prior medium-term ambition of adjusted EBIT margin of 8-10% would no longer be met by the end of its next fiscal year.
Following these disclosures, Alstom's stock price fell sharply, damaging investors.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
Deployment of Alstom’s new-generation, train-centric CBTC system, suited for Lausanne’s existing automated metro line Increased service frequency and passenger capacity for the m2 metro, the backbone of public transport in the Lausanne regionComprehensive modernisation of the train fleet as part of a service strategy to ensure long-term operational performance 5 May 2026 – Transports publics de la région lausannoise (tl) and Alstom have signed a contract worth 295 million euros1 to modernise Lausanne’s m2 metro line. The project will enable more frequent services and increased passenger capacity through the deployment of a new communications based train control (CBTC) system, combined with the mid-life modernisation of the existing train fleet.
The m2 metro is the backbone of public transport in the Lausanne region. The new signalling system will allow trains to operate closer together with greater precision, enabling more trains to run on the line, reducing waiting times and supporting growing passenger demand, while maintaining the highest levels of safety and reliability.
The Urbalis Fluence CBTC solution selected for the project uses a train‑centric architecture, with more intelligence onboard to maximise capacity and operational flexibility while limiting infrastructure changes and additional trackside equipment. It is well suited to modernising existing, fully automated metro lines, improving performance while making best use of current assets and enabling phased upgrades aligned with long‑term network strategies.
Alongside the signalling upgrade, the m2 fleet will undergo a major mid‑life modernisation at Alstom’s site in Villeneuve in Switzerland, effectively extending the lifetime of the metro cars. The FlexCare Modernise programme will consist in renewing key onboard systems, notably the train control and monitoring system (TCMS), which will be fully integrated with the new CBTC signalling, as well as in enhancements to interior areas and a refresh of trains’ exterior. Together, these upgrades will unlock higher capacity, improved reliability and a smoother passenger experience, demonstrating Alstom’s capability to deliver complex mid-life modernisation programmes fully integrated with advanced digital signalling systems.
Patricia Solioz Mathys, CEO of TL, emphasises the importance of modernisation: “As Switzerland’s only metro system, m2 is a real success story. The need to modernise the automation systems and increase capacity is crucial for the whole transport network in the Lausanne metropolitan area. We are delighted to be able to rely on Alstom’s expertise and knowledge in carrying out these strategic operations.”
“This modernisation will bring more frequent, more reliable journeys for passengers and help the city meet growing demand with shorter waits and a smoother ride. By pairing our new-generation, train-centric CBTC with a fully integrated mid-life upgrade of the fleet, we are boosting capacity while extending the performance of the existing trains for years to come. We are very happy to engage in this new project with tl and look forward to many years of continuous long-standing collaboration ,” said Marie Icardo, Managing Director of Alstom Switzerland.
The agreement also includes technical support and obsolescence management services, securing reliable operation of the m2 line through the transition period and beyond.
The works will be carefully phased to minimise disruption to daily services. Most installation and testing activities will be carried out during short night time windows, ensuring that passenger services can be maintained throughout the programme. This reflects the brownfield nature of the project, integrating a new generation CBTC system into a fully operational metro line.
About tl
Transports publics de la région lausannoise (tl) design, organise and operate daily public transport services for some 360,000 passengers. Every day, more than 2,000 staff members help to keep the network running. As a key player in the region and a recognised partner of local authorities, the tl contributes to the economic and social development of the Olympic capital.
ALSTOM™, Urbalis Fluence™ and FlexCare Modernise™ are protected trademarks of the Alstom Group.
About AlstomAlstom is the pure rail leader, committed to making rail the backbone of sustainable transport. We design and deliver a complete range of future-ready solutions – from high-speed and regional trains to metros, monorails, trams, turnkey systems, end-to-end services, infrastructure, signalling and digital rail solutions. With 86,000 people in 63 countries, Alstom brings together global expertise and local know-how to make every journey smarter, cleaner and more enjoyable. Together with our partners and customers, we realise the power of rail. Listed in France, Alstom generated revenues of €18.5 billion for the fiscal year ending 31 March 2025.For more information, please visit www.alstom.com
1 This order was booked in the 4th quarter of Alstom’s 2025/2026 financial year. It is the order referred to in the Note to Investors published on 8 April 2026 (“Alstom signs a new Signalling contract in Europe”).
, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Alstom S.A. ("Alstom" or the "Company") (OTCMKTS: ALSMY; AOMFF). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Alstom and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On April 16, 2026, Alstom S.A. announced preliminary unaudited results for the fiscal year ended March 31, 2026. Among other things, the Company disclosed that it manufactured 4,284 cars during the fiscal year and that adjusted EBIT margin stood at around 6%. The Company further disclosed that "some large rolling-stock projects have progressed more slowly than anticipated," weighing on near-term margins and cash. In addition, Alstom disclosed free cash flow of approximately €330 million, withdrew its three-year cumulative €1.5 billion free cash flow guidance, and said that its prior medium-term ambition of adjusted EBIT margin of 8-10% would no longer be met by the end of its next fiscal year.
Following these disclosures, Alstom's stock price fell sharply, damaging investors.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Alstom S.A. (“Alstom” or the “Company”) (OTCMKTS: ALSMY; AOMFF). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Alstom and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On April 16, 2026, Alstom S.A. announced preliminary unaudited results for the fiscal year ended March 31, 2026. Among other things, the Company disclosed that it manufactured 4,284 cars during the fiscal year and that adjusted EBIT margin stood at around 6%. The Company further disclosed that “some large rolling-stock projects have progressed more slowly than anticipated,” weighing on near-term margins and cash. In addition, Alstom disclosed free cash flow of approximately €330 million, withdrew its three-year cumulative €1.5 billion free cash flow guidance, and said that its prior medium-term ambition of adjusted EBIT margin of 8-10% would no longer be met by the end of its next fiscal year.
Following these disclosures, Alstom’s stock price fell sharply, damaging investors.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
13 May 2026 - Alstom, global leader in smart and sustainable mobility, reports financial results for the fiscal year FY 2025/26. Martin Sion, Chief Executive Officer of Alstom, said:
, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Alstom S.A. ("Alstom" or the "Company") (OTCMKTS: ALSMY; AOMFF). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Alstom and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On April 16, 2026, Alstom S.A. announced preliminary unaudited results for the fiscal year ended March 31, 2026. Among other things, the Company disclosed that it manufactured 4,284 cars during the fiscal year and that adjusted EBIT margin stood at around 6%. The Company further disclosed that "some large rolling-stock projects have progressed more slowly than anticipated," weighing on near-term margins and cash. In addition, Alstom disclosed free cash flow of approximately €330 million, withdrew its three-year cumulative €1.5 billion free cash flow guidance, and said that its prior medium-term ambition of adjusted EBIT margin of 8-10% would no longer be met by the end of its next fiscal year.
Following these disclosures, Alstom's stock price fell sharply, damaging investors.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Alstom S.A. (“Alstom” or the “Company”) (OTCMKTS: ALSMY; AOMFF). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Alstom and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On April 16, 2026, Alstom S.A. announced preliminary unaudited results for the fiscal year ended March 31, 2026. Among other things, the Company disclosed that it manufactured 4,284 cars during the fiscal year and that adjusted EBIT margin stood at around 6%. The Company further disclosed that “some large rolling-stock projects have progressed more slowly than anticipated,” weighing on near-term margins and cash. In addition, Alstom disclosed free cash flow of approximately €330 million, withdrew its three-year cumulative €1.5 billion free cash flow guidance, and said that its prior medium-term ambition of adjusted EBIT margin of 8-10% would no longer be met by the end of its next fiscal year.
Following these disclosures, Alstom’s stock price fell sharply, damaging investors.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
Information pursuant to article L. 233-8 II of the Code de commerce and articles 223-16 and 223-11 of the AMF General regulation (Règlement général de l’Autorité des marchés financiers)
DateNumber of shares with a nominal value of €7Gross number of
voting rights21 May 2026 462,616,024
462,616,024 About AlstomAlstom is the pure rail leader, committed to making rail the backbone of sustainable transportation. We design and deliver a complete range of future-ready solutions – from high-speed and regional trains to metros, monorails, trams, turnkey systems, end-to-end services, infrastructure, signalling and digital rail solutions. With 87,800 people in 61 countries, Alstom brings together global expertise and multi-local presence to make every journey smarter, cleaner and more enjoyable.
Together with our partners and customers, we realise the power of rail. Listed in France, Alstom generated revenues of €19.2 billion for the fiscal year ending 31 March 2026.
For more information, please visit www.alstom.com.
, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Alstom S.A. ("Alstom" or the "Company") (OTCMKTS: ALSMY; AOMFF). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Alstom and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On April 16, 2026, Alstom S.A. announced preliminary unaudited results for the fiscal year ended March 31, 2026. Among other things, the Company disclosed that it manufactured 4,284 cars during the fiscal year and that adjusted EBIT margin stood at around 6%. The Company further disclosed that "some large rolling-stock projects have progressed more slowly than anticipated," weighing on near-term margins and cash. In addition, Alstom disclosed free cash flow of approximately €330 million, withdrew its three-year cumulative €1.5 billion free cash flow guidance, and said that its prior medium-term ambition of adjusted EBIT margin of 8-10% would no longer be met by the end of its next fiscal year.
Following these disclosures, Alstom's stock price fell sharply, damaging investors.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY TO ANY U.S. PERSON OR ANY PERSON LOCATED IN THE UNITED STATES OF AMERICA OR IN ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS PRESS RELEASE.
10 June 2026 – Alstom successfully placed yesterday an inaugural European Green, perpetual and deeply subordinated (‘Hybrid’) Bonds issuance with a principal amount of €700 million, as part of its €1.5 billion Euro Medium Term Notes (EMTN) Programme, published on June 3rd 2026 by the Autorité des Marchés Financiers (AMF).
The bonds bear a fixed rate coupon of 5.25% per annum for the first 5.25 years and a resettable rate every 5 years thereafter. They are direct, unconditional, unsecured, undated and deeply subordinated obligations (titres subordonnés de dernier rang) of the issuer. Moody’s has assigned a 50% equity content to the bonds1 and a Ba2 rating, two notches below Alstom's Baa3 senior unsecured rating.
This first green transaction was multiple times oversubscribed, reflecting strong demand across geographies and investor classes, and supporting further diversification of the investor base.
The proceeds of this transaction will be used to finance and refinance in full the assets and/or expenditures described in the European Green Bond Factsheet, available on Alstom’s website and reviewed by Moody’s, in accordance with the EuGB regulations.
With this inaugural EU Green Bond issuance, Alstom reaffirms its commitment to its Investment Grade rating, while advancing its objective of accelerating the transition to low-carbon mobility and driving sustainable value across its operations and solutions.
The €700 million bond due in October 2026 is expected to be repaid upon maturity.
Credit Agricole Corporate and Investment Bank acted as green structuring bank.
BNP Paribas, Credit Agricole Corporate and Investment Bank, HSBC, and Natixis acted as global coordinators and joint bookrunners for the issuance. Banco Bilbao Vizcaya Argentaria, S.A., Deutsche Bank and Société Générale acted as active bookrunners. Herbert Smith Freehills Kramer acted as legal advisors to Alstom and A&O Shearman as legal advisors to the banks.
About Alstom Alstom is the pure rail leader, committed to making rail the backbone of sustainable transport. We design and deliver a complete range of future-ready solutions – from high-speed and regional trains to metros, monorails, trams, turnkey systems, end-to-end services, infrastructure, signalling and digital rail solutions. With 87,800 people in 61 countries, Alstom brings together global expertise and local know-how to make every journey smarter, cleaner and more enjoyable. Together with our partners and customers, we realise the power of rail. Listed in France, Alstom generated revenues of €19.2 billion for the fiscal year ending 31 March 2026.
For more information, please visit www.alstom.com. Contacts Press:
Charles-Etienne LEBATARD [email protected]
This press release is for information purposes only and is not an offer to sell securities or a solicitation to buy securities in any jurisdiction. The securities mentioned in this press release were not and will not be offered through a public offering and no related documents will be distributed to the public in any jurisdiction. This press release does not constitute an offer or sale of any securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful under the securities laws of any such jurisdiction. Securities may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended. Alstom does not intend to register any of the securities mentioned in this announcement in the United States or to conduct a public offering of securities in the United States. This press release shall not be released, published or distributed directly or indirectly to any U.S. Person or in or into the United States (each as defined in Regulation S under the U.S. Securities Act of 1933, as amended) or in any jurisdiction where it is unlawful to release, publish or distribute this press release.
This press release is an advertisement and not a prospectus for the purposes of Regulation (EU) 2017/1129 of the European Parliament and of the Council dated 14 June 2017 (as amended, the “Prospectus Regulation”). The final prospectus, when published, will be available on the website of the Autorité des marches financiers (www.amf-france.org) and on the website of the Issuer (www.alstom.com).
1 Alstom will account for the bonds entirely as equity under IFRS
THE WOODLANDS, Texas--(BUSINESS WIRE)--Perma-Pipe International Holdings, Inc. (Nasdaq: PPIH), a global leader in pre-insulated piping and leak detection systems, today announced the appointment of Nancy Zakhour and Saleh Sagr to its Board of Directors, effective April 8, 2026. Ms. Zakhour will serve as an independent director and a member of the Board's Audit, Compensation, and Nominating and Corporate Governance Committees. Mr. Sagr will serve as a director. Ms. Zakhour is a dynamic energy ex.
Perma-Pipe International Holdings, Inc. (NASDAQ:PPIH – Get Free Report) shares crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $28.91 and traded as high as $32.49. Perma-Pipe International shares last traded at $31.62, with a volume of 84,157 shares trading hands.
Analysts Set New Price Targets PPIH has been the topic of several research analyst reports. Weiss Ratings upgraded shares of Perma-Pipe International from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Monday, February 23rd. Wall Street Zen upgraded shares of Perma-Pipe International from a “hold” rating to a “strong-buy” rating in a research note on Saturday, December 13th. Finally, Loop Capital set a $36.00 price target on shares of Perma-Pipe International in a research note on Tuesday, December 16th. One equities research analyst has rated the stock with a Buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $36.00.
Check Out Our Latest Stock Analysis on Perma-Pipe International
Perma-Pipe International Price Performance The company has a market capitalization of $255.81 million, a P/E ratio of 18.60 and a beta of 0.57. The firm’s fifty day moving average is $30.72 and its 200 day moving average is $28.91. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.53 and a current ratio of 1.76.
Institutional Investors Weigh In On Perma-Pipe International A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Invesco Ltd. acquired a new position in Perma-Pipe International during the 4th quarter valued at approximately $2,914,000. Royce & Associates LP acquired a new position in Perma-Pipe International during the 3rd quarter valued at approximately $2,146,000. 683 Capital Management LLC acquired a new position in Perma-Pipe International during the 4th quarter valued at approximately $1,122,000. Russell Investments Group Ltd. acquired a new position in Perma-Pipe International during the 3rd quarter valued at approximately $805,000. Finally, Millennium Management LLC increased its stake in Perma-Pipe International by 265.1% during the 4th quarter. Millennium Management LLC now owns 42,780 shares of the industrial products company’s stock valued at $1,299,000 after purchasing an additional 31,064 shares in the last quarter. Hedge funds and other institutional investors own 28.43% of the company’s stock.
Perma-Pipe International Company Profile (Get Free Report)
Perma-Pipe International Holdings Ltd. is a publicly traded company on the NASDAQ under the symbol PPIH that specializes in the design, manufacture and installation of prefabricated piping systems. Its core business revolves around factory-assembled thermal insulation and corrosion protection solutions, including pre-insulated pipe, heat tracing, field-applied jackets and specialty spool pieces. These engineered systems are custom-built to industry specifications and are used to maintain temperatures, control heat loss and extend the life of critical piping infrastructure.
The company’s products and services serve a diverse range of end markets, with primary focus on oil and gas production, petrochemical processing, power generation, district energy, and industrial facilities.
Recommended Stories Five stocks we like better than Perma-Pipe International Receive News & Ratings for Perma-Pipe International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perma-Pipe International and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEAllen Mooney & Barnes Investment Advisors LLC Acquires 633 Shares of Eli Lilly and Company $LLY
NEXT HEADLINE »China Gold International Resources (OTCMKTS:JINFF) Share Price Passes Above 200 Day Moving Average – Time to Sell?
THE WOODLANDS, Texas--(BUSINESS WIRE)--Perma-Pipe International Holdings, Inc. (NASDAQ: PPIH) today announced financial results for the fourth quarter and 2025 fiscal year ended January 31, 2026.
“For the three months ended January 31, 2026, net sales were $55.1 million, an increase of $10.1 million, or 22.4%, compared to $45.0 million in the same quarter of the prior year. Growth was driven by higher sales volumes in both the Middle East and North America. Gross profit was $17.3 million, up $2.1 million from $15.2 million last year, reflecting higher activity levels. Selling, general and administrative expenses increased slightly to $10.3 million from $9.7 million, primarily due to higher payroll costs, partially offset by lower bonus costs. The Company’s effective tax rate (“ETR”) was 12.3%, compared to 32.1% in the prior-year quarter, reflecting the impact of product mix across various tax jurisdictions. As a result, net income attributable to common stock was $4.9 million, an increase of $3.1 million, or 172.2%, compared to $1.8 million in the fourth quarter of fiscal 2024,” noted President and CEO Saleh Sagr.
“For the year ended January 31, 2026, net sales were $210.9 million, an increase of $52.5 million, or 33.1%, compared to $158.4 million in the prior year period. The increase was primarily attributable to higher sales volumes in both the Middle East and North America. Gross profit was $69.5 million, compared to $53.2 million in the prior year period, reflecting increased activity levels. Selling, general and administrative expenses were $40.1 million, up from $32.9 million, due to higher payroll and professional fees, including approximately $1.0 million related to Sarbanes-Oxley Section 404 compliance in connection with our transition from a non-accelerated filer to an accelerated filer. This also includes a one-time compensation charge of approximately $2.0 million related to the departure of the previous CEO. The Company’s effective tax rate was 24.9%, compared to 29.1% in the prior-year period. The change in the Company's effective tax rate reflects product mix across various tax jurisdictions and the Company’s overall reduction in its effective tax rate for the year was partially offset by the impact of a tax limitation related to the one-time charge associated with the prior CEO’s departure. Net income attributable to common stock was $17.0 million, an increase of $8.0 million, or 88.9%, compared to $9.0 million in fiscal 2024,” Mr. Sagr commented.
President and CEO Saleh Sagr added: “Our backlog stood at $121.6 million as of January 31, 2026. This reflects strong operational execution as we successfully accelerated the conversion of existing sales orders into realized revenue. Our backlog remains at historically strong levels. We continue to see meaningful multi-regional expansion, particularly across North America and the Middle East, reinforcing sustained global demand for our solutions.”
“Our fiscal 2025 results represent a landmark achievement for the Company. Total revenues of $210.9 million and net income attributable to common stockholders of $17.0 million mark our highest level of earnings in the Company’s modern operating history, driven not only by strong top-line growth but also by improved margins. This record performance was driven by broad-based strength across our global footprint, with significant growth contributions from the Middle East and North America. Our ability to scale across these diverse markets while maintaining disciplined margin performance has enabled us to convert top-line momentum into meaningful bottom-line value for our shareholders.”
“To sustain this trajectory, we have entered into a long-term lease for a new production facility in Ohio (AI data centers). This strategically located hub will serve as a primary logistics center for the Northeast and New England corridors, enabling us to localize production for our district heating and cooling offerings and capture additional regional market share. The region’s favorable and flexible labor environment further enhances our operational agility.”
“Supporting our long-term growth strategy, we also finalized a new credit facility with J.P. Morgan Chase. This agreement represents a watershed moment for the Company. We have standardized our borrowing platform globally at significantly improved terms. This transition optimizes our cost of capital while providing the liquidity necessary to support the next phase of our global expansion,” Mr. Sagr continued.
“With record earnings as our foundation and a modernized capital structure as our fuel, we enter the remainder of 2026 with strong confidence in our ability to scale our global operations and drive meaningful shareholder returns,” Mr. Sagr concluded.
2025 Results
Net sales were $210.9 million for the fiscal year ended January 31, 2026, an increase of $52.5 million, or 33.1%, from $158.4 million in the prior year. The growth was primarily driven by higher sales volumes across our key markets in the Middle East, Canada, and the United States
Gross profit was $69.5 million, or 33% of net sales, compared to $53.2 million, or 34% of net sales, in the prior year. The $16.3 million was driven by higher sales volumes and consistent gross margins globally.
General and administrative expenses were $35.3 million, compared to $28.0 million in the prior year. The increase of $7.3 million was primarily related to higher compensation costs and professional fees, including approximately $1.0 million relating to Sarbanes-Oxley 404 compliance in connection with our transition from a non-accelerated filer to an accelerated filer. This also includes a one-time compensation charge of approximately $2.0 million related to the departure of the previous CEO.
Selling expenses were $4.7 million, compared to $4.9 million in the years ended January 31, 2026 and 2025, respectively. The decrease of $0.2 million was primarily driven by lower payroll expenses during the year.
Interest expense, net was $1.8 million and $1.9 million in the years ended January 31, 2026 and 2025, respectively. The decrease of $0.1 million was the result of an overall reduction in interest rates during the year.
The Company's worldwide effective tax rates ("ETR") were 24.9% and 29.1% in the years ended January 31, 2026 and 2025, respectively. The change in ETR was largely due to changes in the mix of income and loss in various tax jurisdictions and the domestic Global Intangible Low-Taxed Income ("GILTI") inclusion.
Net income attributable to common stock was $17.0 million, or $ 2.09 per diluted share, for the fiscal year ended January 31, 2026, compared to $9.0 million, or $ 1.12 per diluted share, in the prior year. The 89% increase was driven by the significant growth in sales volumes and operational efficiencies discussed above, partially offset by the one-time charges previously noted and amounts attributable to non-controlling interest.
Perma-Pipe International Holdings, Inc.
Perma-Pipe International Holdings, Inc. (the “Company”) is a global leader in pre-insulated piping and leak detection systems for oil and gas gathering, district heating and cooling, and other applications. It uses its extensive engineering and fabrication expertise to develop piping solutions that solve complex challenges regarding the safe and efficient transportation of many types of liquids. In total, the Company has operations at thirteen locations in seven countries.
Forward-Looking Statements
Certain statements and other information contained in this press release that can be identified by the use of forward-looking terminology constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby, including, without limitation, statements regarding the expected future performance and operations of the Company. These statements should be considered as subject to the many risks and uncertainties that exist in the Company's operations and business environment. Such risks and uncertainties include, but are not limited to, the following: (i) fluctuations in the price of oil and natural gas and its impact on customer order volume for the Company's products; (ii) the Company’s ability to purchase raw materials at favorable prices and to maintain beneficial relationships with its suppliers; (iii) decreases in government spending on projects using the Company’s products, and challenges to the Company’s non-government customers’ liquidity and access to capital funds; (iv) the Company’s ability to repay its debt and renew expiring international credit facilities; (v) the Company’s ability to effectively execute its strategic plan and achieve sustained profitability and positive cash flows; (vi) the Company's ability to collect a long-term account receivable related to a project in the Middle East; (vii) the Company’s ability to interpret changes in tax regulations and legislation; (viii) the Company's ability to use its net operating loss carryforwards; (ix) reversals of previously recorded revenue and profits resulting from inaccurate estimates made in connection with the Company’s "over-time" revenue recognition; (x) the Company’s failure to establish and maintain effective internal control over financial reporting; (xi) the timing of order receipt, execution, delivery and acceptance for the Company’s products; (xii) the Company’s ability to successfully negotiate progress-billing arrangements for its large contracts; (xiii) aggressive pricing by existing competitors and the entrance of new competitors in the markets in which the Company operates; (xiv) the Company’s ability to manufacture products free of latent defects and to recover from suppliers who may provide defective materials to the Company; (xv) reductions or cancellations of orders included in the Company’s backlog; (xvi) risks and uncertainties specific to the Company's international business operations; (xvii) the Company’s ability to attract and retain senior management and key personnel; (xviii) the Company’s ability to achieve the expected benefits of its growth initiatives; (xix) the impact of pandemics and other public health crises on the Company and its operations; and (xx) the impact of cybersecurity threats on the Company’s information technology systems. Shareholders, potential investors and other readers are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements made herein are made only as of the date of this press release and we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. More detailed information about factors that may affect our performance may be found in our filings with the Securities and Exchange Commission, which are available at https://www.sec.gov and under the Investor Center section of our website (http://investors.permapipe.com.)
The Company's fiscal year ends on January 31. Years, results, and balances described as 2025, 2024, and 2023 are for the fiscal year ending January 31, 2026, 2025, and 2024, respectively.
Additional information regarding the Company's financial results for the fiscal year ended January 31, 2026, including management's discussion and analysis of the Company's financial condition and results of operations, is contained in the Company's Annual Report on Form 10-K for the fiscal year ended January 31, 2026, which will be filed with the Securities and Exchange Commission on or about the date hereof and will be accessible at www.sec.gov and www.permapipe.com. For more information, visit the Company's website.
PERMA-PIPE INTERNATIONAL HOLDINGS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data)
(Unaudited)
Three Months Ended January 31,
Year Ended January 31,
2026
2025
2026
2025
Net sales
$
55,129
$
44,987
$
210,925
$
158,384
Gross profit
17,337
15,171
69,488
53,248
Total operating expenses
10,367
9,732
40,039
32,947
Income from operations
6,970
5,439
29,449
20,301
Interest expense, net
505
451
1,822
1,940
Other (expense) income, net
(58
)
262
(134
)
107
Income before income taxes
6,407
5,250
27,493
18,468
Income tax expense
787
1,685
6,844
5,377
Net income
$
5,620
$
3,565
$
20,649
$
13,091
Less: Net income attributable to non-controlling interest
702
1,805
3,614
4,108
Net income attributable to common stock
$
4,918
$
1,760
$
17,035
$
8,983
Weighted average common shares outstanding
Basic
8,103
7,983
8,047
7,956
Diluted
8,206
8,073
8,148
8,015
Earnings per share
Basic
$
0.61
$
0.22
$
2.12
$
1.13
Diluted
$
0.60
$
0.22
$
2.09
$
1.12
Note: Earnings per share calculations could be impacted by rounding.
PERMA-PIPE INTERNATIONAL HOLDINGS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands)
(Unaudited)
January 31,
2026
2025
ASSETS
Current assets
$
146,734
$
108,802
Long-term assets
70,752
56,439
Total assets
$
217,486
$
165,241
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities
$
79,789
$
54,063
Long-term liabilities
31,396
28,073
Total liabilities
111,185
82,136
Non-controlling interests
15,663
10,967
Stockholders' equity
90,638
72,138
Total liabilities and stockholders' equity
$
217,486
$
165,241
PERMA-PIPE INTERNATIONAL HOLDINGS, INC. AND SUBSIDIARIES
RECONCILIATION OF NON-GAAP FINANCIAL MEASURE
ADJUSTED INCOME BEFORE TAX
(In thousands)
(Unaudited)
The following information contains a reconciliation of the non-GAAP financial measure of adjusted income before income tax and income before tax prepared in accordance with generally accepted accounting principles ("GAAP") for the three and twelve months ended January 31, 2026, and 2025, respectively. This reconciliation is intended to provide investors with useful information in evaluating the Company's performance. Adjusted income before tax includes certain adjustments as identified below. This measure is not considered an alternative to income before tax or other financial measures of performance that are prepared in accordance with GAAP. The Company believes that the exclusion of certain items from income before tax allows investors to more effectively evaluate the Company's operating performance and identify trends that might not be apparent due to the variability and infrequent nature of these items. In addition, the Company believes this measure provides meaningful information to investors when comparing results between periods and performance with respect to the Company's peers.
Adjustments were made for certain items as follows: (i) a one-time charge associated with the acceleration of executive compensation; (ii) a one-time litigation settlement charge; and (iii) other non-recurring items. These non-GAAP measures are provided to enhance the user's overall understanding of the company’s current financial performance and may not be comparable to similarly titled measures used by other companies.
The following table provides a reconciliation of the GAAP and non-GAAP financial measures:
For the three months ended
For the twelve months ended
January 31,
2026
January 31,
2025
January 31,
2026
January 31,
2025
Income before income tax (GAAP as reported)
$
6,407
$
5,250
$
27,493
$
18,468
Acceleration of certain executive compensation
-
-
2,018
-
Litigation settlement
-
-
-
35
Other one-time charges
-
-
88
517
Adjusted income before tax
$
6,407
$
5,250
$
29,599
$
19,020
More News From Perma-Pipe International Holdings, Inc.
Perma-Pipe is upgraded to BUY after a post-earnings pullback, with fundamentals improving and risk/reward now attractive. PPIH delivered 33% sales growth in 2025, with Q4 sales up 22% year-over-year and EPS of $0.60, beating expectations. Order backlog remains historically high despite a sequential decline, reflecting strong execution and robust revenue conversion.
Perma-Pipe International (PPIH +1.50%) stock is a little-known microcap stock (market cap under $300 million) that has huge growth potential stemming from 3 main catalysts:
The eventual rebuilding needs of the Middle East following the Iran war; Middle East economic growth and modernization in general; The surging global artificial intelligence (AI) data center build-out, which should be a multiyear phenomenon.
Image source: Perma-Pipe International.
When the Iran war ends, the Middle East will have major and long-lasting rebuilding needs The United States-Israel war against Iran, which began on Feb. 28, expanded to include much of the Middle East. Prior to the recent, temporary ceasefire, Iran had been striking U.S. military bases and other targets located in Middle Eastern countries that it considers to be complicit with the U.S. and Israel.
When the war ends, the Middle East will face major, long-lasting rebuilding needs, as its infrastructure has been severely damaged. Stocks of select companies that are involved in this rebuilding should get a significant boost.
The companies that should benefit most from the rebuilding are those that are small enough that rebuilding work will move the needle for their finances. Investors should also favor companies with growth catalysts beyond rebuilding work. Perma-Pipe International meets these criteria.
Perma-Pipe's key stock stats Company/Index
Market Cap
Trailing P/E
1-Year Stock Change
5-Year Stock Change
Perma-Pipe International $244 million
14.4
153%359%S&P 500 Index --
--
38.7%82% Data sources: Yahoo! Finance, YCharts, and finviz.com. P/E = price-to-earnings ratio. Data to April 21, 2026.
Here are some positive financial points:
Cash flow positive, not just net income positive Insiders own nearly 11% of shares Low trailing-12-month price-to-earnings (P/E) ratio of 14.4 Manageable debt-to-equity ratio
Today's Change
(
1.50
%) $
0.38
Current Price
$
25.65
Perma-Pipe: Business snapshot Perma-Pipe describes itself as a "global leader in engineered pipe services, offering a robust portfolio of capabilities in insulation solutions, containment systems, anti-corrosion coatings, engineering and technical support, material sciences, custom fabrication and leak detection technology."
The Woodlands, Texas-based company's primary traditional end markets are oil and gas, and district energy (heating and cooling). Its newest end market is the AI-enabled data center market.
District energy systems have "one or more central plants producing hot water, steam, and/or chilled water, which then flows through a network of insulated pipes to provide hot water, space heating, and/or air conditioning for nearby buildings," according to the U.S. Department of Energy.
These systems, which are highly energy-efficient, are often found in urban central business districts, college campuses, airports, industrial complexes, and -- notably for the Middle East's rebuilding and modernization needs -- military bases.
Perma-Pipe has 14 operating locations across seven countries, with a heavy concentration in the U.S., Canada, and the Middle East.
Revenue breakdown by country in the fiscal year ended Jan. 31, 2026:
U.S.: 28% Canada: 23% United Arab Emirates (UAE): 22% Saudi Arabia: 22% Other: 5% Perma-Pipe looks poised to benefit from the rebuilding of the Middle East Perma-Pipe is small enough that rebuilding contracts could send its revenue and earnings soaring. Moreover, it has a strong presence -- and, by extension, existing connections -- in the Middle East, a region that has been helping fuel its robust recent growth.
Indeed, Perma-Pipe has called growing its Saudi Arabia business a "strategic priority," and has expanded its manufacturing capabilities in the country. This makes good sense given that the country ranks as the largest economy in the Persian Gulf, driven largely by its massive oil production and exports.
A huge catalyst for its oil and gas market came in September 2025 In September, Perma-Pipe announced that its Saudi Arabian business unit had received formal technical and commercial approval from state-owned Saudi Aramco, the world's largest oil company.
"This approval significantly expands Perma-Pipe's business opportunities in the Kingdom, enabling the Company to directly serve the oil and gas sector," it said in the press release. Until this time, Perma-Pipe's access to the Saudi market was primarily limited to district heating and cooling. "With this new approval, the Company is now well-positioned to participate in Saudi Arabia's pipe coating market, the largest in the Middle East and among the largest globally."
A relatively new growth catalyst: AI data center market Perma-Pipe has entered the data center market, which is experiencing explosive growth driven by the rapid adoption and advances in AI. It has won contracts in this business since at least 2025.
Revenue from this market is likely still a small share of its overall total, but it's growing rapidly. And with Perma-Pipe's expertise in cooling systems and leak detection systems, it has strong growth potential in this market, both in the U.S. and the Middle East.
Indeed, on March 19, Perma-Pipe issued a press release updating investors on its plans to accelerate growth by investing in a manufacturing facility in the Northeast U.S. region, primarily to serve AI data center customers. It expects the facility to become operational in the second quarter of 2026.
Perma-Pipe's Middle East ties provide an opportunity -- but also increase its risk level In that same release, the company updated investors on the status of its Middle East operations. "Despite ongoing regional conflicts, our business operations have not been impacted. We have implemented comprehensive business continuity plans designed to mitigate potential risks and aim to ensure uninterrupted service to our customers and maintain operational stability and safety across all our facilities," CEO Saleh Sagr said.
Data by YCharts.
Perma-Pipe's financials On April 16, Perma-Pipe released its fourth-quarter and full-year results for fiscal 2025, which ended Jan. 31, 2026. For the year, net sales were $210.9 million, up 33% year over year. Growth was primarily driven by higher sales volumes in the Middle East and North America.
Net income was $17.0 million, up 89% from the prior year, translating into earnings per share (EPS) soaring 87% to $2.09. Growth was driven by higher sales, improved margins, and a lower effective income tax rate stemming from the mix of jurisdictions in which sales were made. Absent the latter factor, earnings growth was still strong with net income before income taxes surging 49%.
U.S. businesses usually pay significantly lower corporate income taxes in Saudi Arabia than in the U.S., which should be a long-term positive for Perma-Pipe's profits.
Backlog remains at historically high levels. It was $121.6 million at the end of fiscal 2025, down somewhat from $138.1 million at the start of the fiscal year.
The company does not provide guidance. But its backlog, combined with CEO comments in the earnings release, suggests it is poised for another great year in fiscal 2026 and beyond.
Perma-Pipe stock has huge growth potential, but also a higher risk level Perma-Pipe International has huge growth potential stemming from 3 main catalysts: (1) eventual rebuilding needs of the Middle East, (2) Middle East economic growth and modernization in general, and (3) the surging global AI data center build-out, which should be a multiyear phenomenon.
Moreover, the district cooling market in Saudi Arabia and the UAE, in particular, is projected to grow at a good clip, as these countries build large-scale mixed-use projects.
However, the company's heavy concentration in the Middle East makes it vulnerable to risks stemming from the Iran war and future conflicts in the region. Its small size relative to competitors also increases its risk level. But with its growth dynamics and low P/E ratio, it is a stock that risk-tolerant investors might find attractive.
Shares of Perma-Pipe International Holdings, Inc. (PPIH - Free Report) have declined 12.4% since the company reported its earnings for the quarter ended Jan. 31, 2026, underperforming the S&P 500 index’s 1.1% growth over the same period. Over the past month, however, the stock has gained 4%, lagging the broader market’s 8.2% increase.
Perma-Pipe reported fourth-quarter fiscal 2025 GAAP earnings per share (EPS) of 60 cents, which increased sharply from 22 cents in the prior-year quarter.
Net sales rose 22.4% to $55.1 million from $45 million a year earlier, while net income attributable to common stock climbed 172.2% to $4.9 million.
Operational Performance and Key MetricsThe company’s gross profit for the quarter increased to $17.3 million from $15.2 million in the prior-year period, supported by higher activity levels across its markets.
Operating income also improved, reaching $7 million in the fourth quarter versus $5.4 million a year earlier.
The company ended the quarter with a backlog of $121.6 million, indicating sustained demand and strong order conversion into revenues. This backlog level remains historically high, suggesting continued visibility into future revenue streams.
Factors Influencing PerformanceGrowth in both the quarter and full year was primarily driven by higher sales volumes in key regions, particularly the Middle East and North America. Management highlighted that increased activity levels contributed to higher gross profit, while improved operational execution enabled the company to convert backlog into realized revenues more efficiently.
Expenses increased moderately during the quarter, with selling, general and administrative costs rising to $10.3 million from $9.7 million, largely due to higher payroll expenses.
Tax dynamics also played a role in profitability. The effective tax rate declined significantly in the fourth quarter to 12.3% from 32.1% in the prior year, boosting net income.
Management Commentary and Strategic DirectionManagement characterized fiscal 2025 as a “landmark” year, citing record revenue and earnings driven by broad-based global growth. CEO Saleh Sagr emphasized that expansion across North America and the Middle East, combined with disciplined margin management, enabled the company to translate top-line growth into substantial bottom-line gains.
The company also pointed to strong operational execution, particularly in accelerating backlog conversion, as a key contributor to performance. Management expressed confidence in sustaining growth momentum, supported by continued demand across its global footprint.
Fiscal 2025 UpdateFor fiscal 2025, revenues increased 33.1% to $210.9 million, and EPS rose to $2.09 from $1.12, reflecting an 89% increase in net income attributable to common stock, which reached $17 million.
Gross profit rose to $69.5 million compared to $53.2 million, though margins remained relatively stable at around one-third of net sales. Operating income climbed to $29.4 million from $20.3 million.
Other DevelopmentsDuring the quarter, Perma-Pipe took several steps to support its long-term growth strategy. The company entered into a long-term lease for a new production facility in Ohio, aimed at enhancing logistics capabilities and capturing additional market share in the Northeast and New England regions. Additionally, it finalized a new credit facility with J.P. Morgan Chase, standardizing its global borrowing platform and improving access to liquidity at more favorable terms.
These initiatives, combined with record financial performance, position the company to expand its operations further while maintaining financial flexibility.
Listen to the audio version of this article (generated by AI).
Tom Yeung here with your Sunday Digest.
Right now, Wall Street is crowding into the same handful of stocks. Everyone owns the same mega-caps and semiconductor names. Everyone is chasing the same returns. And everyone assumes interest rates are staying higher for longer.
That’s exactly why I think smaller stocks may be one of the most interesting opportunities in the market today.
Last week, I introduced three small-cap stocks from InvestorPlace Senior Analyst Louis Navellier’s “Exclusion List” — a group of 53 smaller companies his system has flagged as unusually well positioned for the next phase of the market.
The timing was important. Last Wednesday, the Senate confirmed Kevin Warsh as the 17th chairman of the Federal Reserve. Warsh has historically favored lower interest rates, and Louis believes the market may still be underestimating the odds of lower rates later this year.
Now, to be clear, there’s still plenty of uncertainty here. Gasoline and food prices are rising fast, and most investors believe that inflation could force the Fed to keep rates higher for longer – or even hike rates.
But that’s exactly the point.
When “everyone knows” the same thing, opportunities tend to emerge elsewhere — especially in smaller companies that Wall Street often ignores.
Today, I want to introduce you to three more small-cap stocks from Louis’ Exclusion List.
And if you’d like to see the full list of 53 stocks — along with Louis’ full case for why he believes we may be entering one of the most important small-cap opportunities in years — you can watch the limited-time replay of his presentation right here.
Exclusion List Small-Cap Stock to Buy No. 1: Data Centers… and Oil? It’s been an excellent several quarters for our first company. AI data center construction has caused shortages throughout the construction supply chain, and shares of this Houston-based firm have risen 130% since 2025:
Perma-Pipe International Holdings Inc. (PPIH).
Perma-Pipe is a manufacturer of specialty piping systems – the insulated, layered pipes that go into everything from heating and cooling systems to oil and gas pipelines. The company also sells leak-detection systems.
These products have caught on with data centers. Roughly 30% to 40% of an AI data center’s total energy usage goes into cooling, so better-insulated piping quickly becomes a cost advantage.
Conveniently, Perma-Pipe sells arguably the world’s widest range of these insulated pipes. Its XTRU-THERM product line, for instance, can operate as low as -320°F, while its TRACE-THERM goes up to 1,200°F. They also offer corrosion-resistant pipes, budget pipes, fire-retardant pipes, and so on.
Demand for Perma-Pipe’s products has proved insatiable. In March 2026, management announced it would add a new production facility in Ohio specifically for AI data centers. Revenues were up 33% last year.
Even better, Perma-Pipe is an oil and gas play hiding in plain sight.
In the early 2020s, the company began expanding into the Middle East. Governments in Saudi Arabia, Qatar, and beyond were seeking suppliers for their district cooling projects (centralized air conditioning at enormous scale), and Perma-Pipe turned out to be a convenient “one-stop-shop” for these megaprojects. Not only did the American firm offer a wide variety of pipes for municipal cooling, but they could also supply oil and gas pipelines crucial to the region’s economy. This vastly simplified the approvals process and led to the construction of multiple Perma-Pipe factories in the region.
In fact, Perma-Pipe’s expansion was so successful that the company eventually promoted the head of its Middle East operations, Saleh Sagr, to CEO in 2025.
The near-closure of the Strait of Hormuz has now put pipeline megaprojects back on the table. Over the past several months, the Saudi government has floated the idea of expanding its East-West pipeline to avoid the blockade of the Persian Gulf. The United Arab Emirates is exploring a second pipeline to increase current capacity to the Gulf of Oman. Syria and Israel have both suggested building pipelines through to the Mediterranean to bypass the contested region entirely.
Any of these projects could provide a windfall for Perma-Pipe, which generated roughly half of its sales from the Middle East in 2025. Oil and gas pipelines require far more piping than single data center projects, and even repairing the damage from Iranian strikes could cost billions.
And so, AI data centers and the need for new infrastructure in the Middle East give Perma-Pipe two distinct catalysts beyond interest rates. Analysts are projecting only an 8% increase in revenues this year (and zero earnings growth), which I believe understates the opportunity the firm has ahead of it.
And if investors do pivot toward smaller-cap stocks as rates get cut, then PPIH’s strong run may still have room to keep going.
Exclusion List Small-Cap Stock to Buy No. 2: Backup to the Future The second pick today is a battery maker that’s also quickly turning itself into an AI data center supplier:
Electrovaya Inc. (ELVA).
This Canadian small-cap built its business around high-end lithium-ion batteries for electric forklifts and other warehouse equipment. This core market helped drive 43% sales growth last year and helped flip the firm from negative profits to positive.
It’s important to note that Electrovaya uses a proprietary ceramic composite separator (CCS) called SEPARION in its products. This allows batteries to last three to five times longer than normal and charge up far faster – making them less likely to catch fire. (Meanwhile, normal lithium-ion batteries use a thinner plastic-like membrane that’s prone to softening and shrinking.)
These are extremely important features for forklifts for warehouses (where fires can be devastating) and have allowed ELVA to land major customers like Walmart Inc. (WMT) and Home Depot Inc. (HD).
But the more compelling story is where Electrovaya is going next: robotics, automation, defense, and (most importantly) AI data center energy storage.
In April 2025, the company began battery system assembly at its new 52-acre “gigafactory” in Jamestown, New York. The company plans to begin lithium-ion cell and module production in mid-2026, and much of this is aimed at powering the next generation of robots, drones, and AI data centers.
For AI data centers, Electrovaya is developing an 800-volt DC battery system specifically to meet a new standard set by Nvidia Corp. (NVDA). AI chips require far more energy than before (so higher voltages are ideal), and batteries are needed to supply energy during the crucial minutes it takes to start up diesel generators or switch power sources. As every high schooler with a writing project knows, even a split-second power outage can prove catastrophic for data recovery. Electrovaya’s SEPARION technology is particularly well suited for high voltages, where fire risks are high.
The firm expects commercial deliveries to start in 2027.
Meanwhile, Electrovaya’s energy-dense 48V batteries should prove essential for robots and drones, where batteries are constantly charged and discharged. Revenues are expected to rise another 35% this year before accelerating to a 50% growth rate in fiscal 2027 as its Jamestown gigafactory reaches full scale.
Exclusion List Small-Cap Stock to Buy No. 3: The Toyo Alternative Last week, I flagged Toyo Corp. (TOYO) as a stock to buy. The company recently acquired a 1-gigawatt solar manufacturing plant in Texas and plans to expand it to 2.5GW this year. Import tariffs and rising electricity prices mean that Toyo should see strong demand for its highly efficient solar panels.
However, Toyo’s fraud risk is quite high due to its complex holding structure – somewhat typical of Japanese companies – and numerous related-party transactions. Its auditor also has a long history of failing regulatory inspections. And so, I’d like to flag an alternative solar maker this week:
Tigo Energy Inc. (TYGO).
The Silicon Valley-based company has a far simpler corporate structure and a more reputable auditor, Deloitte & Touche.
It also has a similar growth profile, with revenues expected to compound 26% annually through 2028. Profits are expected to flip positive this year, a historically bullish sign.
Tigo’s “secret sauce” is its flagship product, the TS4 Module-Level Power Electronics (MLPE) optimizer.
Ordinarily, solar arrays are limited by their weakest panel. Uneven aging or passing clouds create bottlenecks, reducing the output of the whole system. TS4 MLPE optimizers solve this problem with some electrical engineering, allowing every panel to run closer to its maximum output. And unlike rivals like SolarEdge Technologies Inc. (SEDG) and Enphase Energy Inc. (ENPH), Tigo’s products do not rely on proprietary inverters.
That makes Tigo’s products popular among the “repowering” market. Homeowners can add Tigo’s TS4 optimizers to old systems without tearing existing pieces out, and revenues from this segment have jumped to 20% of total U.S. sales. The systems are also popular among utilities, wary of locking themselves into SolarEdge’s or Enphase’s proprietary systems.
The company also does quite well in foreign markets, especially Europe and Australia. Both regions are seeing higher electricity prices, and I expect solar installations to rise as utilities seek alternatives to fossil fuels.
And so, shares look highly reasonable at $4 today. Demand for solar energy is rising, and Tigo provides an essential piece of that puzzle.
Investing Away from the Crowd Earlier on, I pointed out that most investors see near-zero chance of a rate cut this year. “Everyone knows” rates are staying high.
Yet, six months ago, everyone also “knew” it was Kevin Hassett (not Kevin Warsh) who would be the next Federal Reserve Chair. Futures markets “knew” that oil would trade at $56 by the end of 2026.
That’s why investing against the crowd sometimes works so well. You’re getting into trades before anyone realizes what’s going on. And even if rates aren’t cut this year, these three picks should still perform well.
PPIH is growing revenues 33% annually and sits at the center of both the AI data center buildout and a potential Middle East pipeline boom. ELVA is ramping a gigafactory to supply batteries for robots, drones, and Nvidia-spec data centers. TYGO is riding a global solar surge with a product that works with any existing system. These three picks – and the other three from last week — are just a starting point.
Louis has identified 53 small caps positioned to benefit if the new Fed begins cutting rates, and he explains exactly why he believes those cuts are coming in his brand-new, free presentation.
This broadcast is only available for a limited time, so I urge you to watch it now before it goes offline.
Until next week,
Thomas Yeung, CFA
Market Analyst, InvestorPlace
Thomas Yeung is a market analyst and portfolio manager of the Omnia Portfolio, the highest-tier subscription at InvestorPlace. He is the former editor of Tom Yeung’s Profit & Protection, a free e-letter about investing to profit in good times and protecting gains during the bad.
THE WOODLANDS, Texas--(BUSINESS WIRE)--Perma-Pipe International Holdings, Inc. (NASDAQ: PPIH) announced today financial results for the first quarter ended April 30, 2026. “For the three months ended April 30, 2026, net sales increased 7.5% to $50.3 million, compared to $46.7 million in the prior-year quarter, driven by higher sales volumes in both North America and the MENA region. Gross profit was $14.6 million, compared to $16.7 million in the first quarter of fiscal 2025. The decrease in gr.
Meet the TELUS SmartHome Assistant -- one intelligent interface to manage all smart home devices, designed and powered in Canada
, /CNW/ - Today, TELUS launched the world's first smart home AI assistant with Generative UI, rolling out to SmartHome+ customers over the coming weeks. The TELUS SmartHome Assistant processes voice, images, sensor feeds and videos in real time to dynamically create a personalized interface based on user needs. It addresses the smart home industry's biggest challenge -- a fragmented user experience across disparate devices and apps from various brands. Rather than toggling between different apps, the TELUS SmartHome Assistant provides one intuitive interface that truly understands and responds to the user and the entire connected home. TELUS is making it possible to unify more than 2,000 device models, including many of the biggest brands, into a single intelligent interface that makes the connected home experience even better.
"The true test of any smart home platform is whether it actually makes life easier and your home more enjoyable. The TELUS SmartHome Assistant delivers that with one app, one login, and one AI assistant that can support thousands of smart devices, including those already existing in homes or ones consumers choose to buy to compliment their existing set-up," said Dwayne Benefield, Chief Product Officer at TELUS. "Nothing else like it exists in the market. We're proud to not only bring this to Canadians, but also to service providers on a global scale who can customize and deploy this innovation under their own brands. TELUS is truly transforming an entire industry, and there's so much more in store: In the coming weeks, TELUS SmartHome Assistant will launch internet management capabilities, enabling users to monitor and optimize Wi-Fi performance and manage family usage and screen time through natural conversation and automated actions across devices."
The TELUS SmartHome Assistant is evolving in real time as more connected devices are added and it continuously improves its own performance based on experience. If you ask it to disable the TV during homework time, it won't just tell you it did, it will build the automation UI visually, so you can edit and confirm the new routine with just a few taps. Take a photo of a device that isn't working and get an instant troubleshooting guide. Ask it if your dog walker showed up on schedule and it checks your cameras to tell you when they arrived and shows you a clip of them leaving the driveway. Rush out the door to get to work, and ask it to turn off the lights, make sure the iron's unplugged, set the thermostat to eco mode, and lock the front door -- then get it to create a routine, so you can set it and forget it. By understanding multiple types of input, the assistant can provide tailored solutions, with a dynamic interface, in real time.
Since launching SmartHome+ in late 2024, TELUS has rapidly expanded the platform with industry-leading innovations, including Automation, Video, SmartEnergy, and now its AI-powered assistant, the TELUS SmartHome Assistant -- all accessible through the TELUS SmartHome+ app.
TELUS SmartHome Assistant is available now to all Canadians, and new subscribers to SmartHome+ can save up to $125 on smart devices and 50 per cent off professional installation when they sign up and stay subscribed for 24 months, making it more affordable than ever to transform a residence into an intelligent, cohesive and connected home.
For more information about SmartHome+ and to subscribe to any or all of the Automation, SmartHome+ Video and SmartEnergy subscriptions, visit telus.com/SmartHomePlus.
About TELUS
TELUS (TSX: T, NYSE: TU) is a world-leading communications technology company operating in more than 45 countries and generating over $20 billion in annual revenue with more than 21 million customer connections through our advanced suite of broadband services for consumers, businesses and the public sector. We are committed to leveraging our technology to enable remarkable human outcomes. TELUS is passionate about putting our customers and communities first, leading the way globally in client service excellence and social capitalism. TELUS Health is enhancing more than 161 million lives across 200 countries and territories through innovative preventive medicine and well-being technologies. TELUS Agriculture & Consumer Goods utilizes digital technologies and data insights to optimize the connection between producers and consumers. TELUS Digital specializes in digital customer experiences and future-focused digital transformations that deliver value for their global clients. Guided by our enduring 'give where we live' philosophy, TELUS continues to invest in initiatives that support education, health and community well-being. In 2023, we launched the TELUS Student Bursary, which strives to ensure that every young person in Canada who wants a postsecondary education has the opportunity to pursue one. To date, the program has distributed over $6 million in bursaries to 2,000 students and counting. Since 2000, TELUS, our team members and retirees have contributed $1.85 billion in cash, in-kind contributions, time and programs, including 2.5 million days of service--earning TELUS the distinction of the world's most giving company.
For more information, visit telus.com or follow @Darren_Entwistle on Instagram.
For more information, please contact:
Chelsey Higdon
TELUS Public Relations
[email protected]
